AU2011317880B2 - Quinoxaline derivates - Google Patents

Abstract

Compounds of the formula (I) in which R, R

Description

- 1 Quinoxaline derivatives BACKGROUND OF THE INVENTION The invention provides compounds having valuable properties, in particular those which can be used for the preparation of medicaments. The present invention relates to compounds and the use thereof for the modulation, in particular for the inhibition, of the activity or function of the phosphoinositide 3'-OH kinase family (hereinafter P13 kinases), advantage ously P13Ka, P13K6, P13Kp and/or P13Ky. The present invention advanta geously relates to the use of quinoxaline derivatives in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, blood platelet aggregation, cancer, sperm motility, transplant rejection, graft rejection and lung injuries. Cell membranes provide a large store of secondary messengers that can be enlisted in a variety of signal transduction pathways. As regards the function and regulation of effector enzymes in phospholipid signalling pathways, these enzymes generate secondary messengers from the membrane phospholipid pools. Class I P13 kinases (for example P13Ka) are dual-specificity kinase enzymes, i.e. they exhibit both lipid kinase activ ity (phosphorylation of phosphoinositides) and protein kinase activity, shown to be capable of phosphorylation of protein as substrate, including autophosphorylation as intramolecular regulatory mechanism. These enzymes of phospholipid signalling are activated by various extracellular signals, such as growth factors, mitogens, integrins (cell-cell interactions), hormones, cytokines, viruses, and neurotransmitters, as described in Scheme I below, and also by intracellular regulation by other signaling WO 2012/052102 PCT/EP2011/004746 -2 molecules (cross-talk, where the original signal can activate some parallel pathways, which in a second step transmit signals to PI3Ks by intracellular signaling events), such as, for example, small GTPases, kinases, or phos 5 phatases. Intracellular regulation can also occur as a result of aberrant expression or lack of expression of cellular oncogenes or tumour suppres sors. The intracellular inositol phopholipid (phosphoinositide) signaling pathways begin with activation of signaling molecules (extracellular ligands, stimuli, receptor dimerisation, transactivation by a heterologous 10 receptor (for example receptor tyrosine kinase) and with the recruitment and activation of P13K, including the involvement of G protein-linked trans membrane receptor integrated into the plasma membrane. 15 P13K converts the membrane phospholipid PI(4.5)P 2 into PI(3,4,5)P 3 , which functions as secondary messenger. PI and PI(4)P are likewise sub strates of P13K and can be phosphorylated and converted into P13P and PI(3,4)P 2 , respectively. In addition, these phosphoinositides can be con 20 verted into other phosphoinositides by 5-specific and 3-specific phos phatases, meaning that P13K enzyme activity results either directly or indi rectly in the generation of two 3'-phosphoinositide subtypes which function as secondary messengers in intracellular signal transduction pathways (Trends Biochem. Sci. 22(7) pp. 267-72 (1997) by Vanhaesebroeck et al; 25 Chem. Rev. 101(8) pp. 2365-80 (2001) by Leslie et al (2001); Annu. Rev. Cell. Dev. Biol. 17p, 615-75 (2001) by Katso et al. and Cell. Mol. Life Sci. 59(5) pp. 761-79 (2002) by Toker et al.). Multiple P13K isoforms catego rised by their catalytic subunits, their regulation by corresponding regula 30 tory subunits, expression patterns and signal-specific functions (p1 10, , 6 and y) perform this enzyme reaction (Exp. Cell. Res. 25 (1) pp. 239-54 (1999) by Vanhaesebroeck and Katso et al., 2001, see above). 35 The closely related isoforms p11 Oa and p are expressed ubiquitously, while 8 and y are expressed more specifically in the haematopoietic cell WO 2012/052102 PCT/EP2011/004746 -3 system, in the smooth muscle cells, myocytes and endothelial cells (Trends Biochem. Sci. 22(7) pp. 267-72 (1997) by Vanhaesebroeck et al.). Their expression can also be regulated in an inducible manner depending 5 on the cellular tissue type and stimuli as well as in accordance with the particular disease. The inducibility of protein expression includes protein synthesis as well as protein stabilisation, which is partly regulated by asso ciation with regulatory subunits. 10 To date, eight mammalian PI3Ks have been identified, divided into 3 main classes (I, II and Ill) on the basis of sequence homology, structure, binding partners, mode of activation, and substrate preference. In vitro, class I Pl3Ks are able to phosphorylate phosphatidylinositol (PI), phosphatidyl 15 inositol 4-phosphate (P14P) and phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) to give phosphatidylinositol 3-phosphate (PI3P), phosphatidyl inositol 3,4-bisphosphate (PI(3,4)P2, and phosphatidylinositol 3,4,5-tris phosphate (PI(3,4,5)P 3 , respectively. Class Il P13Ks phosphorylate PI and 20 phosphatidylinositol 4-phosphate. Class Ill P13Ks can only phosphorylate PI (Vanhaesebroeck et al., 1997, see above; Vanhaesebroeck et al., 1999, see above, and Leslie et al, 2001, see above). 25 30 35 WO 2012/052102 PCT/EP2011/004746 -4 Scheme 1: Conversion of PI(4,5)P2 into PIP3 0 H OH OH 15 0 ,0 -0 04 Oo H oHPI3 \_ H OHH 10inositol ring 'H 0 0 Ptdlns(4.5)P, 0 15 oO P O P13K \/ H O P/ H 52 04 20P H OHH OH 25H As illustrated in Scheme I above, phosphoinositide 3-kinases (Pl3Ks) phosphorylate the hydroxyl of the third carbon atom on the inositol ring. The phosphorylation of phosphoinositides which converts Ptdins into 3,4,5 triphosphate (Ptdlns(3,4,5)P 3 ), Ptdins(3,4)P 2 and Ptdlns(3)P produces 30 secondary messengers for various signal transduction pathways, as are essential, inter alia, for cell proliferation, cell differentiation, cell growth, cell size, cell survival, apoptosis, adhesion, cell mobility, cell migration, chemotaxis, invasion, cytoskeletal rearrangement, cell shape changes, 35 vesicle trafficking and metabolic pathway (Katso et al, 2001, see above, and Mol. Med. Today 6(9) pp. 347-57 (2000) by Stein). G protein-coupled WO 2012/052102 PCT/EP2011/004746 receptors mediate phosphoinositide 3'-OH kinase activation via small GTPases, such as Gpy and Ras, and consequently P13K signaling plays a central role in the development and coordination of cell polarity and 5 dynamic organisation of the cytoskeleton - which together provide the driving force for cell movement. Chemotaxis - the directed movement of cells in the direction of a concentration gradient of chemical attractants, which are also called 10 chemokines, is also involved in many important diseases, such as inflammation/autoimmunity, neurodegeneration, angiogenesis, invasion/metastasis and wound healing (Immunol. Today 21(6) pp. 260-4 (2000) by Wyman et al.; Science 287(5455) pp. 1049-53 (2000) by Hirsch 15 et al.; FASEB J. 15(11) pp. 2019-21 (2001) by Hirsch et al., and Nat. Immunol. 2(2) pp. 108-15 (2001) by Gerard et al.). Advances using genetic approaches and pharmacological tools have pro 20 vided insights into signalling and molecular pathways which promote chemotaxis in response to chemical attractant-activated, G protein-coupled sensors. P13 kinase, which is responsible for the generation of these phosphorylated signalling products, was originally identified as an activity which is associated with viral oncoproteins and growth factor tyrosine 25 kinases which phosphorylate phosphatidylinositol (P1) and its phosphorylated derivatives at the 3'-hydroxyl of the inositol ring (Panayotou et al., Trends Cell Biol. 2 pp. 358-60 (1992)). However, more recent biochemical studies have shown that class I P13 kinases (for 30 example class IB isoform P13Ky) are dual-specificity kinase enzymes, which means that they exhibit both lipid kinase activity and protein kinase activity, shown to be capable of phosphorylation of other proteins as substrates, as well as autophosphorylation as an intramolecular regulatory 35 mechanism.

WO 2012/052102 PCT/EP2011/004746 -6 P13 kinase activation is therefore probably involved in various cellular responses, including cell growth, differentiation and apoptosis (Parker et al., Current Biology, 5 pp. 577-99 (1995); Yao et al., Science, 267 pp. 2003-05 (1995)). P13 kinases appear to be involved in a number of 5 aspects of leukocyte activation. A p85-associated P13 kinase activity has been shown to associate physically with the cytoplasmic domain of CD28, which is an important co-stimulatory molecule for the activation of T cells by antigen (Pages et al., Nature, 369 pp. 327-29 (1994); 10 Rudd, Immunity 4 pp. 527-34 (1996)). Activation of T cells by CD28 lowers the threshold for activation by antigen and increases the mag nitude and duration of the proliferative response. These effects are accompanied by increases in the transcription of a number of genes, 15 such as, inter alia, interleukin-2 (IL2), an important T cell growth factor (Fraser et al., Science 251 pp. 313-16 (1991)). If CD28 is mutated in such a way that it can no longer interact with P13 kinase, initiation of IL 2 production fails, which suggests a crucial role for P13 kinase in T cell 20 activation. P13Ky has been identified as a promoter of G-p-y-dependent regulation of JNK activity, and G-p-y are subunits of heterotrimeric G proteins (Lopez-llasaca et al, J. Biol. Chem. 273(5) pp. 2505-8 (1998)). Cellular processes in which P13Ks play an essential role include sup pression of apoptosis, reorganisation of the actin skeleton, cardiac 25 myocyte growth, glycogen synthase stimulation by insulin, TNFa-pro moted neutrophil priming and superoxide generation, and leukocyte migration and adhesion to endothelial cells. 30 Laffargue et al., Immunity 16(3) pp. 441-51 (2002), have described that P13Ky relays inflammatory signals via various G(i)-coupled receptors and that it is crucial for mast cell function, stimuli in connection with leukocytes, and immunology, including cytokines, chemokines, adenosines, 35 antibodies, integrins, aggregation factors, growth factors, viruses or hormones (J. Cell. Sci. 114(Pt 16) pp. 2903-10 (2001) by Lawlor et al.; WO 2012/052102 PCT/EP2011/004746 -.7 Laffargue et al., 2002, see above, and Curr. Opinion Cell Biol. 14(2) pp. 203-13 (2002) by Stephens et al.). 5 Specific inhibitors against individual members of a family of enzymes provide invaluable tools for deciphering the functions of each enzyme. Two compounds, LY294002 and wortmannin (see below), have been widely used as P13 kinase inhibitors. These compounds are non-specific P13K inhibitors, since they do not distinguish between the four members of class 10 I P13 kinases. For example, the IC 50 values of wortmannin against each of the various class I P13 kinases are in the range from I to 10 nM. Correspondingly, the IC 50 values of LY294002 against each of these P13 kinases are about 15 to 20 pM (Fruman et al., Ann. Rev. Biochem., 67, pp. 15 481-507 (1998)), in addition it has IC 50 values of 5 - 10 pM on CK2 protein kinase and a slight inhibitory activity on phospholipases. Wortmannin is a fungal metabolite which irreversibly inhibits P13K activity by bonding covalently to the catalytic domain of this enzyme. The inhibition of P13K 20 activity by wortmanin eliminates the subsequent cellular response to the extracellular factor. For example, neutrophils respond to the chemokine fMet-Leu-Phe (fMLP) by stimulation of P13K and synthesis of Ptdlns (3, 4, 5)P 3 . This synthesis correlates with activation of the respiratory burst which is involved in the destruction of the neutrophils of invading micro 25 organisms. Treatment of neutrophils with wortmannin prevents the fMLP induced respiratory burst response (Thelen et al., Proc. NatI. Acad. Sci. USA, 91, pp. 4960-64 (1994)). Indeed, these experiments with wortmannin, as well as other experimental evidence, show that P13K 30 activity in cells of haematopoietic lineage, in particular neutrophils, monocytes and other types of leukocytes, are involved in many of the non memory immune response associated with acute and chronic inflammation. 35 WO 2012/052102 PCT/EP2011/004746 0 CH3ON 0 I

CH

3 Q 0 N. N) 0 100 LY294002 Wortmannin Based on studies with wortmannin, there is evidence that P13 kinase func 15 tion is also necessary for some aspects of leukocyte signalling by G pro tein-coupled receptors (Thelen et al., 1994, see above). In addition, it has been shown that wortmannin and LY294002 block neutrophil migration and superoxide release. Carboxygenase-inhibiting benzofuran derivatives 20 are disclosed by John M. Janusz et al., in J. Med. Chem. 1998; Vol. 41, No. 18. It is now well understood that deregulation of oncogenes and tumour-sup pressor genes contributes to the formation of malignant tumours, for 25 example by increasing cell growth and proliferation or increased cell sur vival. It is now also known that signalling pathways promoted by the P13K family play a central role in a number of cell processes, such as, inter alia, in proliferation and survival, and deregulation of these pathways is a 30 causative factor in a broad spectrum of human cancer diseases and other diseases (Katso et al., Annual Rev. Cell Dev. Biol, 2001, 17: 615-617, and Foster et al, J. Cell Science. 2003, U6: 3037-3040). 35 Class I P13K is a heterodimer consisting of a catalytic p110 subunit and a regulatory subunit, and the family is further divided into class ]a and class WO 2012/052102 PCT/EP2011/004746 lb enzymes on the basis of the regulatory partners and the regulation mechanisms. Class la enzymes consist of three different catalytic subunits (p1 10a, p1 10p, and p1108), which dimerise with five different regulatory 5 subunits (p85a, p55a, p50ax, p850 and p557), where all catalytic subunits are able to interact with all regulatory subunits to form various hetero dimers. Class la PI3Ks are generally activated in response to growth factor stimulation of receptor tyrosine kinases via interaction of the regulatory SH2 domain subunit with specific phosphotyrosine residues of the acti 10 vated receptor or adaptor proteins, such as IRS-1. Small GTPases (for example ras) are likewise involved in the activation of P13K together with receptor tyrosine kinase activation. Both p110a and p110p are constitu tively involved in all cell types, whereas p1106 expression is more 15 restricted to leukocyte populations and some epithelial cells. By contrast, the only class lb enzyme consists of a catalytic p11 0y subunit, which inter acts with a regulatory p101 subunit. In addition, the class lb enzyme is activated by G protein-coupled receptor (GPCR) systems, and its expres 20 sion appears to be limited to leukocytes. There is now clear evidence showing that class la P13K enzymes contrib ute to tumorigenesis in a large number of human cancer diseases, either 25 directly or indirectly (Vivanco and Sawyers, Nature Reviews Cancer, 2002, 2, 489-501). For example, the p11Occ subunit is amplified in some tumours, such as, for example, in ovarian tumours (Shayesteh, et al., Nature Genetics, 1999, 21: 99-102) and cervix (Ma et al, Oncogene, 2000, 19: 2739-2744). Recently, activating mutations in p110a (PIK3CA gene) have 30 been associated with various other tumours, such as, for example, colon and breast and lung tumours (Samuels, et al, Science, 2004, 304, 554). Tumour-related mutations in p85a have likewise been identified in cancer diseases, such as ovarian and colon cancer (Philp et al., Cancer 35 Research, 2001, 61, 7426-7429). Besides direct effects, activation of class I Pl3Ks is probably involved in tumorigenic events occurring upstream of WO 2012/052102 PCT/EP2011/004746 -10 signalling pathways, for example by means of ligand-dependent or ligand independent activation of receptor tyrosine kinases, GPCR systems or integrins (Vara et al., Cancer Treatment Reviews, 2004, 30, 193-204). Examples of such upstream signalling pathways include overexpression of 5 the receptor tyrosine kinase Erb2 in a number of tumours which lead to activation of P13K-promoted pathways (Harari et al., Oncogene, 2000, Jj), 6102-6114) and overexpression of the oncogene Ras (Kauffmann-Zeh et al., Nature, 1997, 385, 544-548). In addition, class la P13Ks may contribute 10 indirectly to tumorigenesis caused by various downstream signalling events. For example, the loss of function of the PTEN tumour-suppressor phosphatase which catalyses the conversion of PI(3,4,5,)P 3 back to PI(4,5)P 2 is associated with a very broad range of tumours via deregulation 15 of the P13K-promoted production of Pl(3,4,5)P 3 (Simpson and Parsons, Exp. Cell Res., 2001, 264, 29-41). In addition, the increase in the effects of other P13K-promoted signalling events probably contributes to a number of cancer diseases, for example by activation of AKT (Nicholson and 20 Andeson, Cellular Signaling, 2002, 14, 381-395). Besides a role in the promotion of proliferative and survival signalling in tumour cells, there is good evidence that class I P13K enzymes also contribute to tumorigenesis via their function in tumour-associated stromal 25 cells. P13K signalling is known to play an important role in the promotion of angiogenic events in endothelial cells in response to pro-angiogenic fac tors, such as VEGF (abid et al., Arterioscler. Thromb. Vasc. Biol., 2004, 24, 294-300). Since class I P13K enzymes are also involved in mobility and 30 migration (Sawyer, Expert Opinion investing. Drugs, 2004, 13, 1-19), P13K inhibitors are thought to provide a therapeutic benefit via inhibition of tumour cell invasion and metastasis. 35 The synthesis of small compounds which specifically inhibit, regulate and/or modulate P13 kinase signal transduction is therefore desirable and an aim of the present invention.

WO 2012/052102 PCT/EP2011/004746 -11 It has been found that the compounds according to the invention and salts thereof have very valuable pharmacological properties while being well toler ated. 5 It has been found that the compounds according to the invention are inhibitors of the phosphoinositide 3-kinases (P13Ks). If the phosphoinositide 3-kinase (P13K) enzyme is inhibited by a compound 10 according to the invention, P13K is unable to exert its enzymatic, biological and/or pharmacological effects. The compounds according to the invention are therefore suitable for the treatment of autoimmune diseases, inflammatory diseases, cardiovascular diseases, neurodegenerative dis 15 eases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, blood platelet aggregation, cancer, sperm motility, transplant rejection, graft rejection and lung injuries. 20 The compounds of the formula (1) are suitable, in particular, as medica ments for the treatment of autoimmune diseases, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, blood platelet aggrega tion, cancer, sperm motility, transplant rejection, graft rejection and lung 25 injuries. According to an embodiment of the present invention, the compounds of the formula (I) are inhibitors of one or more phosphatoinositide 3-kinases (Pl3Ks), advantageously phosphatoinositide 3-kinase y 30 (P13Ky), phosphatoinositide 3-kinase a (Pl3Ka), phosphatoinositide 3-kinase P (Pl3Kp), and/or phosphatoinositide 3-kinase 6 (P13K 6). The compounds of the formula (1) are suitable for the modulation, in par 35 ticular for the inhibition, of the activity of phosphatoinositide 3-kinases (P13Ks), advantageously phosphatoinositide 3-kinase (PI3Ka). The com- WO 2012/052102 PCT/EP2011/004746 - 12 pounds according to the invention are therefore also suitable for the treat ment of disorders which are promoted by P13Ks. The treatment includes the modulation - in particular the inhibition or downregulation - of phos 5 phatoinositide 3-kinases. The compounds according to the invention are preferably used for the pre paration of a medicament for the treatment of a disorder selected from multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythema 10 tosus, inflammatory bowel disease, lung inflammation, thrombosis or brain infection or inflammation, such as meningitis or encephalitis, Alzheimer's disease, Huntington's disease, CNS trauma, stroke or ischaemic states, cardiovascular diseases, such as atherosclerosis, cardiac hypertrophy, 15 cardiac myocyte dysfunction, hypertension or vasoconstriction. The compounds of the formula (1) are preferably suitable for the treatment of autoimmune diseases or inflammatory diseases, such as multiple scle 20 rosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, lung inflammation, thrombosis or brain infec tion or inflammation, such as meningitis or encephalitis. The compounds of the formula (1) are preferably suitable for the treatment 25 of neurodegenerative diseases, such as, inter alia, multiple sclerosis, Alz heimer's disease, Huntington's disease, CNS trauma, stroke or ischaemic states. 30 The compounds of the formula (1) are preferably suitable for the treatment of cardiovascular diseases, such as atherosclerosis, cardiac hypertrophy, cardiac myocyte dysfunction, hypertension or vasoconstriction. 35 The compounds of the formula (1) are preferably suitable for the treatment of chronic obstructive pulmonary disease, anaphylactic shock fibrosis, pso riasis, allergic diseases, asthma, stroke, ischaemic states, ischemia- WO 2012/052102 PCT/EP2011/004746 -13 reperfusion, blood platelet aggregation or activation, skeletal muscle atro phy or hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastasis, in particular melanoma, Karposi's sarcoma, acute and 5 chronic bacterial and viral infections, sepsis, transplant rejection, graft rejection, glomerulosclerosis, glomerulonephritis, progressive renal fibro sis, endothelial and epithelial injuries in the lung, and lung airway inflam mation. 10 Since the pharmaceutically active compounds of the present invention are active as P13 kinase inhibitors, in particular the compounds which inhibit pl3Ka, either selectively or together with one or more of P13K6, PI3Kp and/or PI3Ky, they have therapeutic utility in the treatment of cancer. 15 The invention preferably relates to a method for the treatment of cancer in a mammal, including humans, where the cancer is selected from: brain (gliomas), glioblastomas, leukaemias, Bannayan-Zonana syndrome, Cow 20 den disease, Lhermitte-Duclos disease, breast cancer, inflammatory breast cancer, Wilm's tumour, Ewing's sarcoma, rhabdomyosarcoma, ependymoma, medulloblastoma, colon, head and neck, kidney, lung, liver, melanoma, ovary, pancreas, prostate, sarcoma, osteosarcoma, giant-cell tumour of bone and thyroid. 25 The invention preferably relates to a method for the treatment of cancer in a mammal, including humans, where the cancer is selected from: lympho blastic T-cell leukaemia, chronic myelogenous leukaemia, chronic lympho 30 cytic leukaemia, hairy-cell leukaemia, acute lymphoblastic leukaemia, acute myelogenous leukaemia, chronic neutrophilic leukaemia, acute lym phoblastic T-cell leukaemia, plasmacytoma, immunoblastic large cell leu kaemia, mantle cell leukaemia, multiple myeloma, megakaryoblastic leu 35 kaemia, multiple myeloma, acute megakaryocytic leukaemia, promyelo cytic leukaemia and erythroleukaemia.

WO 2012/052102 PCT/EP2011/004746 - 14 The invention preferably relates to a method for the treatment of cancer in a mammal, including humans, where the cancer is selected from malignant 5 lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, lymphoblastic T-cell lymphoma, Burkitt's lymphoma and follicular lymphoma. The invention preferably relates to a method for the treatment of cancer in a mammal, including humans, where the cancer is selected from: neuro blastoma, bladder cancer, urothelial cancer, lung cancer, vulvar cancer, 10 cervical cancer, endometrial cancer, renal cancer, mesothelioma, oeso phageal cancer, salivary gland cancer, hepatocellular cancer, bowel can cer, nasopharyngeal cancer, buccal cancer, mouth cancer, GIST (gastro intestinal stromal tumour) and testicular cancer. 15 The compounds of the formula I can furthermore be used for the isolation and investigation of the activity or expression of P13 kinase. In addition, they are particularly suitable for use in diagnostic methods for diseases in 20 connection with unregulated or disturbed P13 kinase activity. It can be shown that the compounds according to the invention have an antiproliferative action in vivo in a xenotransplant tumour model. The com pounds according to the invention are administered to a patient having a 25 hyperproliferative disease, for example to inhibit tumour growth, to reduce inflammation associated with a lymphoproliferative disease, to inhibit trans plant rejection or neurological damage due to tissue repair, etc. The pre sent compounds are suitable for prophylactic or therapeutic purposes. As 30 used herein, the term "treatment" is used to refer to both prevention of dis eases and treatment of pre-existing conditions. The prevention of prolif eration is achieved by administration of the compounds according to the invention prior to the development of overt disease, for example to prevent 35 the growth of tumours, prevent metastatic growth, diminish restenosis as sociated with cardiovascular surgery, etc. Alternatively, the compounds are WO 2012/052102 PCT/EP2011/004746 - 15 used for the treatment of ongoing diseases by stabilising or improving the clinical symptoms of the patient. 5 The host or patient can belong to any mammalian species, for example a primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of interest for experimental investigations, providing a model for treatment of human disease. 10 The susceptibility of a particular cell to treatment with the compounds according to the invention can be determined by in vitro tests. Typically, a culture of the cell is combined with a compound according to the invention 15 at various concentrations for a period of time which is sufficient to allow the active agents to induce cell death or to inhibit migration, usually between about one hour and one week. In vitro testing can be carried out using cul tivated cells from a biopsy sample. The viable cells remaining after the treatment are then counted. 20 The dose varies depending on the specific compound used, the specific disease, the patient status, etc. A therapeutic dose is typically sufficient considerably to reduce the undesired cell population in the target tissue while the viability of the patient is maintained. The treatment is generally 25 continued until a considerable reduction has occurred, for example an at least about 50% reduction in the cell burden, and may be continued until essentially no more undesired cells are detected in the body. 30 For identification of a signal transduction pathway and for detection of interactions between various signal transduction pathways, various scien tists have developed suitable models or model systems, for example cell culture models (for example Khwaja et al., EMBO, 1997, 16, 2783-93) and 35 models of transgenic animals (for example White et al., Oncogene, 2001, 20, 7064-7072). For the determination of certain stages in the signal trans duction cascade, interacting compounds can be utilised in order to modu- WO 2012/052102 PCT/EP2011/004746 - 16 late the signal (for example Stephens et al., Biochemical J., 2000, 351, 95-105). The compounds according to the invention can also be used as reagents for testing kinase-dependent signal transduction pathways in ani 5 mals and/or cell culture models or in the clinical diseases mentioned in this application. Measurement of the kinase activity is a technique which is well known to the person skilled in the art. Generic test systems for the determination of 10 the kinase activity using substrates, for example histone (for example Alessi et al., FEBS Lett. 1996, 399, 3, pages 333-338) or the basic myelin protein, are described in the literature (for example Campos-Gonzelez, R. and Glenney, Jr., J.R. 1992, J. Biol. Chem. 267, page 14535). 15 For the identification of kinase inhibitors, various assay systems are avail able. In scintillation proximity assay (Sorg et al., J. of Biomolecular Screen ing, 2002, 7, 11-19) and flashplate assay, the radioactive phosphorylation 20 of a protein or peptide as substrate with yATP is measured. In the pres ence of an inhibitory compound, a decreased radioactive signal, or none at all, is detectable. Furthermore, homogeneous time-resolved fluorescence resonance energy transfer (HTR-FRET) and fluorescence polarisation (FP) technologies are suitable as assay methods (Sills et al., J. of Biomolecular 25 Screening, 2002, 191-214). Other non-radioactive ELISA assay methods use specific phospho-anti bodies (phospho-ABs). The phospho-AB binds only the phosphorylated substrate. This binding can be detected by chemiluminescence using a 30 second peroxidase-conjugated anti-sheep antibody (Ross et al., 2002, Biochem. J.). PRIOR ART 35 Pyrazine derivatives and the use thereof as P13K inhibitors are disclosed in WO 2012/052102 PCT/EP2011/004746 -17 WO 2007/023186 Al. Pyridopyrimidines are described as P13 kinase inhibitors in WO 2009/ 039140 Al. 5 Other quinoxaline derivatives are disclosed as P13K inhibitors in WO 2008/127594. Still other quinoxaline derivatives are described in WO 2008/101979 Al for the treatment of autoimmune diseases, inflammation or cancer. Compared with other quinoxaline derivatives disclosed in WO 2008/101979, the com 10 pounds according to the invention have improved inhibiting properties on P13 kinase (Table 1). Other quinoxaline derivatives for combating cancer are disclosed in 15 WO 2008/021389 A2. Further quinoxaline derivatives for combating cancer are disclosed in WO 2007/044729 A2. SUMMARY OF THE INVENTION 20 The invention relates to compounds of the formula I H 25 N N-R2 N N-S0 2 -R' H in which 30 R denotes H, Hal or A, R4 denotes Het, Ar', A, (CH 2 )nNH 2 , (CH 2 )nNHA,

(CH

2 )nNA 2 ,

(CH

2 )pCN or (CH 2 )pSO 2 A, R2 denotes Ar 2 or Het 2 , 35 Het' denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having I to 4 N, 0 and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, (CH 2

),NH

2

,

WO 2012/052102 PCT/EP2011/004746 - 18 (CH2)nNHA,

(CH

2 )nNA 2 , CF 2

NH

2 , CF 2 NHA, CF 2

NA

2 , (CH2)nCONH 2 , (CH 2 )nCONHA, (CH 2 )nCONA 2 , CN, =0, Hal,

(CH

2 )nOH, (CH 2 )nOA, COOH, COOA, O(CH 2 )nOH, O(CH 2 )nOA, 5

O(CH

2 )nNH 2 , NH(CH 2 )nNH 2 , SO 2 A and/or SO 2

NH

2 , Arl denotes phenyl, naphthyl or biphenyl, each of which is unsubsti tuted or mono-, di- or trisubstituted by CN, (CH 2 )nCONH 2 ,

(CH

2 ),CONHA,

(CH

2 )nCONA 2 , (CH 2 )nOH, (CH 2 )nOA, (CH 2 )nNH 2 ,

(CH

2 )nNHA, (CH 2 )nNA 2 , NHCOOA, NHCOA, Hal, COOH, 10 COOA, COHet, A, NHSO 2 A, SO 2

NH

2 , SO 2 NHA, SO 2

NA

2 and/or SO 2 A,

O-OH

3 O-CH 15 Ar2 denotes ( \ / or { R3 O-A' R3 A' A' denotes unbranched or branched alkyl having 1-4 C atoms, 20 in which 1-5 H atoms may be replaced by F, Het 2 denotes a mono- or bicyclic unsaturated or aromatic heterocycle having 1 to 4 N, 0 and/or S atoms, which is substituted by

OCH

3 and may additionally be substituted by R 4 , 25 R3 denotes Hal, (CH 2 )nHet 3 , O(CH 2 )nHet 3 or unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by OH, F, Cl and/or Br, and/or in which one, two or three non-adjacent

CH

2 groups may be 30 replaced by 0, NH, NA', S, SO, S02 and/or CH=CH groups, R4 denotes (CH 2 )nCONH 2 , (CH 2 )nCONHA,

(CH

2 )nCONA 2 or unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by OH, F, CI and/or Br, and/or in which one, two or three non-adjacent

CH

2 groups may be replaced by 0, NH, NA', S, SO, S02 and/or CH=CH groups, WO 2012/052102 PCT/EP2011/004746 - 19 Het 3 denotes a monocyclic saturated heterocycle having 1 to 4 N, 0 and/or S atoms, which may be unsubstituted or mono- or disub stituted by A, Hal and/or =0, 5 A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F and/or Cl, or cyclic alkyl having 3-7 C atoms, Hal denotes F, Cl, Br or I, 10 p denotes 1, 2, 3, 4, 5 or 6, n denotes 0, 1, 2, 3 or 4, and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, 15 Compounds of the formula I are also taken to mean the hydrates and sol vates of these compounds, furthermore pharmaceutically usable derivatives. 20 The invention also relates to the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and sol vates of these compounds. solvates of the compounds are taken to mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. Solvate are, for example, mono- or 25 dihydrates or alcoholates. Pharmaceutically usable derivatives are taken to mean, for example, the salts of the compounds according to the invention and also so-called pro drug compounds. 30 Prodrug derivatives are taken to mean compounds of the formula I which have been modified by means of, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism to form the effective compounds according to the invention. 35 These also include biodegradable polymer derivatives of the compounds according to the invention, as described, for example, in Int. J. Pharm. 11i5, 61-67 (1995).

WO 2012/052102 PCT/EP2011/004746 - 20 The expression "effective amount" denotes the amount of a medicament or of a pharmaceutical active compound which causes in a tissue, system, 5 animal or human a biological or medical response which is sought or desired, for example, by a researcher or physician. In addition, the expression "therapeutically effective amount" denotes an amount which, compared with a corresponding subject who has not received this amount, has the following consequence: 10 improved treatment, healing, prevention or elimination of a disease, syn drome, condition, complaint, disorder or side effects or also the reduction in the advance of a disease, complaint or disorder. The term "therapeutically effective amount" also encompasses the 15 amounts which are effective for increasing normal physiological function. The invention also relates to the use of mixtures of the compounds of the formula 1, for example mixtures of two diastereomers, for example in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000. 20 These are particularly preferably mixtures of stereoisomeric compounds. The invention relates to the compounds of the formula I and salts thereof and to a process for the preparation of compounds of the formula I and 25 pharmaceutically usable salts, tautomers and stereoisomers thereof, char acterised in that a compound of the formula 11 30 N L N N-SO-R 1 H 35 in which R and R 1 have the meanings indicated in Claim 1, WO 2012/052102 PCT/EP2011/004746 - 21 and L denotes Cl, Br, I or a free or reactively functionally modified OH group, 5 is reacted with a compound of the formula Ill

H

2

N-R

2 11l, in which 10 R2 has the meaning indicated in Claim 1, and/or a base or acid of the formula I is converted into one of its salts. 15 Above and below, the radicals R, R1 and R2 have the meanings indicated in the case of the formula I, unless expressly indicated otherwise. Abbreviations: DCM = dichloromethane 20 DMA = dimethylacetamide DMF = dimethylformamide EA = ethyl acetate PE = petroleum ether 25 RT = room temperature TFA = trifluoroacetic acid A denotes alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 30 6, 7, 8, 9 or 10 C atoms. A preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1- , 1,2- or 2,2-dimethylpropyl, 1-ethyl propyl, hexyl, 1- , 2-, 3- or 4-methylpentyl, 1,1- , 1,2-, 1,3-, 2,2-, 2,3- or 3,3-d imethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-I -methylpropyl, 1 -ethyl-2 methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, further preferably, for exam ple, trifluoromethyl.

WO 2012/052102 PCT/EP2011/004746 -22 A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoro ethyl. 5 Cyclic alkyl (cycloalkyl) preferably denotes cyclopropyl, cyclobutyl, cylo pentyl, cyclohexyl or cycloheptyl. A' denotes alkyl, is unbranched (linear) or branched, and has 1, 2, 3 or 4 C atoms. 10 R preferably denotes H. Ar denotes, for example, phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, 15 o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butyl phenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-aminophenyl, o-, m- or p-(N methylamino)phenyl, o-, m- or p-(N-methylaminocarbonyl)phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-methoxyphenyl, o-, m- or p-ethoxyphenyl, 20 o-, m- or p-ethoxycarbonylphenyl, o-, m- or p-(N,N-dimethylamino)phenyl, o-, m- or p-(N,N-dimethylaminocarbonyl)phenyl, o-, m- or p-(N-ethylamino) phenyl, o-, m- or p-(N,N-diethylamino)phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p- chlorophenyl, o-, m- or p-(methylsulfon amido)phenyl, o-, m- or p-(methylsulfonyl)phenyl, o-, m- or p-methyl 25 sulfanylphenyl, o-, m- or p-cyanophenyl, o-, m- or p-carboxyphenyl, o-, m or p-methoxycarbonylphenyl, o-, m- or p-aminosulfonylphenyl, furthermore preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromo 30 phenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl, 3-nitro-4 chlorophenyl, 3-amino-4-chloro-, 2-amino-3-chloro-, 2-amino-4-chloro-, 2 -amino-5-chloro- or 2-amino-6-chlorophenyl, 2-nitro-4-N,N-dimethyl amino- or 3 -nitro-4-N,N-dimethylaminophenyl, 2,3-diaminophenyl, 2,3,4-, 35 2,3,5-, 2,3,6-, 2,4,6- or 3 ,4,5-trichlorophenyl, 2 ,4,6-trimethoxyphenyl, 2 -hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3

,

6 -dichloro-4-aminophenyl, 4 -fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromo- WO 2012/052102 PCT/EP2011/004746 -23 phenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4 acetamidophenyl, 3-fluoro-4-methoxyphenyl, 3-amino-6-methylphenyl, 3-chloro-4-acetamidophenyl or 2,5-dimethyl-4-chlorophenyl. Het' denotes, irrespective of further substitutions, for example 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, further 10 more preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1 or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4 thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-iso 15 indolyl, indazolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzo pyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7- benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazoly, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazoly, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 20 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4 oxazinyl, further preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-y, 2,1,3-benzoxadiazol-5-yl or dibenzo furanyl. 25 The heterocyclic radicals may also be partially or fully hydrogenated. Irrespective of further substitutions, Het can thus also denote, for example, 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro 2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, 30 -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or 5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4 pyridyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 35 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4 dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1 -, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4- WO 2012/052102 PCT/EP2011/004746 -24 tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1,2,3,4-tetrahydro-1-,-2-, 3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8- 3,4-dihydro-2H benzo-1,4-oxazinyl, further preferably 2,3-methylenedioxyphenyl, 3,4 5 methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-dihydrobenzofuran-5- or 6-yl, 2,3-(2 oxomethylenedioxy)phenyl or also 3,4-dihydro-2H-1,5-benzodioxepin-6- or -7 yl, furthermore preferably 2,3-dihydrobenzofuranyl, 2,3-dihydro-2-oxofuranyl, 3,4-dihydro-2-oxo-1H-quinazolinyl, 2,3-dihydrobenzoxazoly, 2-oxo-2,3 10 dihydrobenzoxazolyl, 2,3-dihydrobenzimidazoly, 1,3-dihydroindole, 2-oxo-1,3 dihydroindole or 2-oxo-2,3-dihydrobenzimidazolyl. HetI particularly preferably denotes piperidinyl, pyrrolidinyl, morpholinyl, 15 piperazinyl, oxazolidinyl, tetrahydrothienyl, thiomorpholinyl, pyrazolyl, pyridinyl, pyrimidinyl, furyl, thienyl, thiazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, isoxazolyl or imidazolidinyl, where the radicals may also be mono-, di- or tri substituted by A, (CH 2 )nNH 2 , (CH 2 )nNHA, (CH 2 )nNA 2 , CF 2

NH

2 , CF 2 NHA, 20 CF 2

NA

2 , (CH 2 )nCONH 2 , (CH 2 )nCONHA,

(CH

2 )nCONA 2 , CN and/or =0. Het 2 denotes, irrespective of further substitutions, for example 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, indazolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7 25 benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benziso thiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H 30 benzo-1,4-oxazinyl, further preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan 6-yl, 2,1,3-benzothiadiazol-4- or -5-yl, 2,1,3-benzoxadiazol-5-yl or dibenzo furanyl. The heterocyclic radicals may also be partially hydrogenated. 35 Irrespective of further substitutions, Het 2 can thus also denote, for example, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1,2,3,4-tetrahydro 1-,-2-,-3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8- 3,4-dihydro- WO 2012/052102 PCT/EP2011/004746 -25 2h-benzo-1,4-oxazinyl, further preferably 2,3-methylenedioxyphenyl, 3,4 methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-dihydrobenzofuran-5- or 6-yl, 2,3-(2 5 oxomethylenedioxy)phenyl or also 3,4-dihydro-2H-1,5-benzodioxepin-6- or -7 yl, furthermore preferably 2,3-dihydrobenzofuranyl, 2,3-dihydro-2-oxofuranyl, 3,4-dihydro-2-oxo-1H-quinazolinyl, 2,3-dihydrobenzoxazolyl, 2-oxo-2,3 dihydrobenzoxazolyl, 2,3-dihydrobenzimidazoly, 1,3-dihydroindole, 2-oxo-1,3 dihydroindole or 2-oxo-2,3-dihydrobenzimidazolyl. 10 Het2 preferably denotes

CH

3 CH 3 I1 I 0 00 15 X R 4 ' X R4 OH OH1 X

R

4 ' 20 X R 4 ' CH CH 3 j3 o 0 X or 25 ?R4

R

4 where X denotes 0, NH or S,

R

4 denotes H, (CH 2 )nCONH 2 , (CH 2 )nCONHA, (CH 2 )nCONA 2 or 30 unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by OH, F, Cl and/or Br, and/or in which one, two or three non-adjacent

CH

2 groups may be replaced by 0, NH, NA', S, SO, S02 and/or CH=CH groups. 35 WO 2012/052102 PCT/EP2011/004746 - 26 Het 2 particularly preferably denotes benzodioxolyl, dihydrobenzofuranyl, dihydrobenzodioxinyl or benzofuranyl, where the radicals are monosubstituted by OCH 3 and may additionally be substituted by R 4 . 53 R3 preferably denotes Hal, (CH 2 )nHet 3 , O(CH 2 )nHet 3 , A', OA', (CH 2 )nNH 2 ,

(CH

2 )nNHA', (CH 2 )nNA 2 , (CH 2 )nOH, (CH 2 )nOA', O(CH 2 )nCHA'OH,

O(CH

2 )nCHA'OA', O(CH 2 )nCHA'(CH 2 )nOH, O(CH 2 )nCHA'(CH 2 )nOA',

O(CH

2 )mSO 2 A', O(CH 2 )mSOA', O(CH 2 )mO(CH 2 )mOH, O(CH 2 )mO(CH 2 )mOA', 10 O(CH2)nCHOH(CH 2 )nOH, O(CH 2 )nSO(CH 2 )nOH, O(CH 2 )nSO 2

(CH

2 )nOH,

O(CH

2 )mNA(CH 2 )mOH, O(CH 2 )mOH, O(CH 2 )mOA', NH(CH 2 )mOH,

NH(CH

2 )nNH 2 or NH(CH 2 )mOA', where m denotes 1, 2, 3 or 4. 15

R

4 preferaby denotes (CH 2 )nCONH 2 , (CH 2 )nCONHA', (CH 2 )nCONA' 2 , A', OA', (CH 2 )nNH 2 , (CH 2 )nNHA', (CH 2 )nNA' 2 , (CH 2 )nOH, (CH 2 )nOA',

O(CH

2 )nCHA'OH, O(CH 2 )nCHA'OA', O(CH 2 )nCHA'(CH 2 )nOH, 20 O(CH 2 )nCHA'(CH 2 )nOA', O(CH 2 )mSO 2 A', O(CH 2 )mSOA',

O(CH

2 )mO(CH 2 )mOH, O(CH 2 )mO(CH 2 )mOA', O(CH 2 )nCHOH(CH 2 )nOH,

O(CH

2 )nSO(CH 2 )nOH, O(CH 2 )nSO 2

(CH

2 )nOH, O(CH 2 )mNA(CH 2 )mOH,

O(CH

2 )mOH, O(CH 2 )mOA', NH(CH 2 )mOH, NH(CH 2 )nNH 2 or NH(CH 2 )mOA', where 25 m denotes 1, 2, 3 or 4. Het 3 preferably denotes piperidinyl, pyrrolidinyl, acetidinyl, morpholinyl, piperazinyl, oxazolidinyl, tetrahydrothienyl, tetrahydropyranyl or thiomor 30 pholinyl, where the radicals may also be mono- or disubstituted by =0, Hal and/or A'. D denotes, irrespective of further substitutions, for example thiazolediyl, thiophenediyl, furandiyl, pyrrolediyl, oxazolediyl, isoxazolediyl, oxadiazole diyl, pyrazolediyl, imidazolediyl, thiadiazolediyl, pyridazinediyl, pyrazinediyl, pyridinediyl or pyrimidinediyl, WO 2012/052102 PCT/EP2011/004746 - 27 where the radicals may also be mono-, di- or trisubstituted by Hal and/or A. Hal preferably denotes F, Cl or Br, but also I, particularly preferably F or Cl. 5 Throughout the invention, all radicals which occur more than once may be identical or different, i.e. are independent of one another. The compounds of the formula I may have one or more chiral centres and can therefore occur in various stereoisomeric forms. The formula I encom 10 passes all these forms. Accordingly, the invention relates, in particular, to the compounds of the formula I in which at least one of the said radicals has one of the preferred 15 meanings indicated above. Some preferred groups of compounds may be expressed by the following sub-formulae la to lh, which conform to the for mula I and in which the radicals not designated in greater detail have the meaning indicated for the formula 1, but in which 20 in la R denotes H; in lb Het' denotes piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, oxazolidinyl, tetrahydrothienyl, thiomorpholinyl, pyrazolyl, 25 pyridinyl, pyrimidinyl, furyl, thienyl, thiazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, isoxazolyl or imidazolidinyl, where the radicals may also be mono-, di- or trisubstituted by A, (CH 2 )nNH 2 , (CH 2 )nNHA, (CH 2 )nNA 2 , CF 2

NH

2 , 30

CF

2 NHA, CF 2

NA

2 , (CH 2 )nCONH 2 , (CH 2 )nCONHA,

(CH

2 )nCONA 2 , CN and/or =0; 35 WO 2012/052102 PCT/EP2011/004746 - 28 tCH3 CH in Ic Het denotes 1 3 5 CH CH X R4' IX R4' 10

CH

3 CH 3 o 3 or IAXR4 R4 15 X denotes O, NH or S, R 4 denotes H, (CH 2 )nCONH 2 , (CH 2 )nCONHA, (CH 2 )nCONA 2 or unbranched or branched alkyl having 1-10 C atoms, in 20 which 1-7 H atoms may be replaced by OH, F, CI and/or Br, and/or in which one, two or three non-adjacent CH 2 groups may be replaced by 0, NH, NA', S, SO, SO 2 and/or CH=CH groups; 25 in Id Het 2 denotes benzodioxolyl, dihydrobenzofuranyl, dihydrobenzo dioxinyl or benzofuranyl, where the radicals are monosub stituted by OCH 3 and may additionally be substituted by R 4 ; 30 in le R3 denotes Hal, (CH 2 )nHet 3 , O(CH 2 )nHet 3 , A', OA',

(CH

2 )nNH 2 , (CH 2 )nNHA', (CH 2 )nNA' 2 , (CH 2 )nOH,

(CH

2 )nOA', O(CH 2 )nCHA'OH,

O(CH

2 )nCHA'OA',

O(CH

2 )nCHA'(CH 2 )nOH, O(CH 2 )nCHA'(CH 2 )nOA', 35 O(CH 2 )mSO 2 A', O(CH 2 )mSOA', O(CH 2 )mO(CH 2 )mOH,

O(CH

2 )mO(CH 2 )mOA', O(CH 2 )nCHOH(CH 2 )nOH, WO 2012/052102 PCT/EP2011/004746 - 29 O(CH 2 )nSO(CH 2 )nOH, O(CH 2 )nSO 2

(CH

2 )nOH,

O(CH

2 )mNA(CH 2 )mOH, O(CH 2 )mOH, O(CH 2 )mOA',

NH(CH

2 )mOH, NH(CH 2 )nNH 2 or NH(CH 2 )mOA', m denotes 1, 2, 3 or 4; in If R 4 denotes (CH 2 )nCONH 2 , (CH 2 )nCONHA', (CH 2 )nCONA' 2 , A', OA, (CH 2 )nNH 2 , (CH 2 )nNHA', (CH 2 )nNA' 2 , (CH 2 )nOH,

(CH

2 )nOA', O(CH 2 )nCHA'OH, O(CH 2 )nCHA'OA', 10

O(CH

2 )nCHA'(CH 2 )nOH, O(CH 2 )nCHA'(CH 2 )nOA',

O(CH

2 )mSO 2 A', O(CH 2 )mSOA', O(CH 2 )mO(CH 2 )mOH,

O(CH

2 )mO(CH 2 )mOA', O(CH 2 )nCHOH(CH 2 )nOH,

O(CH

2 )nSO(CH 2 )nOH, O(CH 2 )nSO 2

(CH

2 )nOH, 15 O(CH 2 )mNA(CH 2 )mOH, O(CH 2 )mOH, O(CH 2 )mOA',

NH(CH

2 )mOH, NH(CH 2 )nNH 2 or NH(CH 2 )mOA', m denotes 1, 2, 3 or 4; 20 in Ig Het 3 denotes piperidinyl, pyrrolidinyl, acetidinyl, morpholinyl, piperazinyl, oxazolidinyl, tetrahydrothienyl, tetrahydropyranyl or thiomorpholinyl, where the radicals may also be mono- or disubstituted by =0, Hal and/or A'; 25 in Ph R denotes H, R1 denotes Het 1 , Ar 1 , A, (CH 2 )nNH 2 , (CH 2 )nNHA,

(CH

2 )nNA 2 , (CH 2 )pCN or (CH 2 )pSO 2 A, R2 denotes Ar2 or Het 2 30 Het' denotes piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, oxazolidinyl, tetrahydrothienyl, thiomorpholinyl, pyrazolyl, pyridinyl, pyrimidinyl, furyl, thienyl, thiazolyl, oxazolyl, oxadiazolyl, imidazoly, pyrrolyl, isoxazolyl or 35 imidazolidinyl, where the radicals may also be mono-, di- or trisubstituted by A, (CH 2 )nNH 2 , (CH 2 )nNHA, WO 2012/052102 PCT/EP2011/004746 -30 (CH2)nNA 2 , CF 2

NH

2 , CF 2 NHA, CF 2

NA

2 , (CH 2 )nCONH 2 ,

(CH

2 )nCONHA, (CH 2 )nCONA 2 , CN and/or =0, Ar denotes phenyl, naphthyl or biphenyl, each of which is 5 unsubstituted or mono-, di- or trisubstituted by CN,

(CH

2

),CONH

2 , (CH 2 )nCONHA, (CH 2 )nCONA 2 , (CH 2 )nOH,

(CH

2 )nOA, (CH 2 )nNH 2 , (CH 2 )nNHA, (CH2)nNA 2 , NHCOOA, NHCOA, Hal, COOH, COOA, COHet 3 , A,

NHSO

2 A, SO 2

NH

2 , SO 2 NHA, SO 2

NA

2 and/or SO 2 A, 10 0-OH OH 21 3 23C Ar2 denotes{ \ / or { PA R3 O-A' R3 A' 15 A' denotes unbranched or branched alkyl having 1-4 C atoms, in which 1-5 H atoms may be replaced by F, CH C

OH

3 OH 20 Het 2 denotes 0 3 0 N

N

0 O R4 O R4 OH

CH

3 25 0 R O R4 X R 4 X R 4 CH CH 3 30 or X denotes 0, NH or S, 35 R3 denotes Hal, (CH 2 )nHet 3 , O(CH 2 )nHet 3 or WO 2012/052102 PCT/EP2011/004746 - 31 unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by OH, F, Cl and/or Br, and/or in which one, two or three non-adjacent CH 2 5 groups may be replaced by 0, NH, NA', S, SO, SO 2 and/or CH=CH groups, R 4 denotes H, (CH 2 )nCONH 2 , (CH 2 )nCONHA, (CH 2 )nCONA 2 or unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by OH, F, CI 10 and/or Br, and/or in which one, two or three non adjacent CH 2 groups may be replaced by 0, NH, NA', S, SO, S02 and/or CH=CH groups, Het 3 denotes piperidinyl, pyrrolidinyl, acetidinyl, morpholinyl, 15 piperazinyl, oxazolidinyl, tetrahydrothienyl, tetrahydro pyranyl or thiomorpholinyl, where the radicals may also be mono- or disubstituted by =0, Hal and/or A', A denotes unbranched or branched alkyl having 1-10 C atoms, 20 in which 1-7 H atoms may be replaced by F and/or Cl, or cyclic alkyl having 3-7 C atoms, Hal denotes F, Cl, Br or I, 25 p denotes 1, 2, 3, 4, 5 or 6, n denotes 0, 1, 2, 3 or 4; and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. 30 The compounds of the formula I and also the starting materials for their preparation are, in addition, prepared by methods known per se, as described in the literature (for example in the standard works, such as 35 Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), to be precise under reaction conditions which are known and suitable for the said reactions. Use can WO 2012/052102 PCT/EP2011/004746 - 32 also be made here of variants known per se which are not mentioned here in greater detail. 5 Compounds of the formula I can preferably be obtained by reacting a com pound of the formula II with a compound of the formula Ill. The starting compounds of the formulae 11 and Ill are generally known. If they are novel, however, they can be prepared by methods known per se. In the compounds of the formula I1, L preferably denotes OH, Cl, Br, I or a free 10 or reactively modified OH group, such as, for example, an activated ester, an imidazolide or alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyl oxy or trifluoromethylsulfonyloxy) or arylsulfonyloxy having 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy). 15 Depending on the conditions used, the reaction time is between a few min utes and 14 days, the reaction temperature is between about -300 and 1800, normally between 30* and 160", in particular between about 40* and about 1200. 20 Examples of suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloro form or dichloromethane; alcohols, such as methanol, ethanol, isopropa 25 nol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as 30 acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro com pounds, such as nitromethane or nitrobenzene; esters, such as ethyl ace 35 tate, or mixtures of the said solvents. Particular preference is given to propanol, ethanol, butanol, ethylene glycol, dioxane, THF or dimethoxyethane.

WO 2012/052102 PCT/EP2011/004746 - 33 Pharmaceutical salts and other forms The said compounds according to the invention can be used in their final 5 non-salt form. On the other hand, the present invention also encompasses the use of these compounds in the form of their pharmaceutically accept able salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of the formula I are for the most part prepared 10 by conventional methods. If the compound of the formula I contains a car boxyl group, one of its suitable salts can be formed by reacting the com pound with a suitable base to give the corresponding base-addition salt. Such bases are, for example, alkali metal hydroxides, including potassium 15 hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine and N-methyl 20 glutamine. The aluminium salts of the compounds of the formula I are like wise included. In the case of certain compounds of the formula 1, acid addition salts can be formed by treating these compounds with pharma ceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, 25 other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoarylsulfonates, such as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoro 30 acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascor bate and the like. Accordingly, pharmaceutically acceptable acid-addition salts of the compounds of the formula I include the following: acetate, adi pate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), 35 bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, diglu conate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethane- WO 2012/052102 PCT/EP2011/004746 - 34 sulfonate, fumarate, galacterate (from mucic acid), galacturonate, gluco heptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydro 5 bromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso butyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphos phate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmo ate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, 10 phosphonate, phthalate, but this does not represent a restriction. Furthermore, the base salts of the compounds according to the invention include aluminium, ammonium, calcium, copper, iron(Ill), iron(ll), lithium, 15 magnesium, manganese(ill), manganese(II), potassium, sodium and zinc salts, but this is not intended to represent a restriction. Of the above-men tioned salts, preference is given to ammonium; the alkali metal salts sodium and potassium, and the alkaline earth metal salts calcium and 20 magnesium. Salts of the compounds of the formula I which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chloroprocaine, 25 choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylamino ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperi dine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, 30 lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, pipera zine, piperidine, polyamine resins, procaine, purines, theobromine, tri ethanolamine, triethylamine, trimethylamine, tripropylamine and tris (hydroxymethyl)methylamine (tromethamine), but this is not intended to 35 represent a restriction.

WO 2012/052102 PCT/EP2011/004746 - 35 Compounds of the present invention which contain basic nitrogen-contain ing groups can be quaternised using agents such as (Cr-C4)alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and 5 iodide; di(C-C 4 )alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (Co-C13)alkyl halides, for example decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl(CI-C4)alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-solu ble compounds according to the invention can be prepared using such 10 salts. The above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisucci 15 nate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and trometh amine, but this is not intended to represent a restriction. 20 Particular preference is given to hydrochloride, dihydrochloride, hydro bromide, maleate, mesylate, phosphate, sulfate and succinate. The acid-addition salts of basic compounds of the formula I are prepared 25 by bringing the free base form into contact with a sufficient amount of the desired acid, causing the formation of the salt in a conventional manner. The free base can be regenerated by bringing the salt form into contact with a base and isolating the free base in a conventional manner. The free 30 base forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts other wise correspond to the respective free base forms thereof. 35 As mentioned, the pharmaceutically acceptable base-addition salts of the compounds of the formula I are formed with metals or amines, such as WO 2012/052102 PCT/EP2011/004746 - 36 alkali metals and alkaline earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, dietha nolamine, ethylenediamine, N-methyl-D-glucamine and procaine. 5 The base-addition salts of acidic compounds according to the invention are prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conven 10 tional manner. The free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional man ner. The free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solu 15 bility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free acid forms thereof. If a compound according to the invention contains more than one group 20 which is capable of forming pharmaceutically acceptable salts of this type, the invention also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, di phosphate, disodium and trihydrochloride, but this is not intended to repre sent a restriction. 25 With regard to that stated above, it can be seen that the expression "phar maceutically acceptable salt" in the present connection is taken to mean an active compound which comprises a compound of the formula I in the 30 form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active compound compared with the free form of the active compound or any other salt form of the active compound used earlier. The pharmaceutically acceptable salt form of the 35 active compound can also provide this active compound for the first time with a desired pharmacokinetic property which it did not have earlier and WO 2012/052102 PCT/EP2011/004746 - 37 can even have a positive influence on the pharmacodynamics of this active compound with respect to its therapeutic efficacy in the body. The invention furthermore relates to medicaments comprising at least one 5 compound of the formula I and/or pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants. 10 Pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active compound per dosage unit. Such a unit can comprise, for example, 0.5 mg to 1 g, prefer ably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a com 15 pound according to the invention, depending on the condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active compound per dosage unit. Preferred dosage unit formulations are those which comprise 20 a daily dose or part-dose, as indicated above, or a corresponding fraction thereof of an active compound. Furthermore, pharmaceutical formulations of this type can be prepared using a process which is generally known in the pharmaceutical art. 25 Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublin gual), rectal, nasal, topical (including buccal, sublingual or transdermal), 30 vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods. Such formulations can be prepared using all processes known in the pharmaceutical art by, for example, combining the active compound with the excipient(s) or adjuvant(s). 35 Pharmaceutical formulations adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; WO 2012/052102 PCT/EP2011/004746 -38 powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions. 5 Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active-ingredient component can be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like. Powders are prepared by 10 comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present. 15 Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith. Glidants and lubricants, such as, for example, highly disperse silicic acid, talc, magnesium stearate, cal 20 cium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation. A disintegrant or solubiliser, such as, for example, agar-agar, calcium carbonate or sodium carbonate, may likewise be added in order to improve the availability of the medica ment after the capsule has been taken. 25 In addition, if desired or necessary, suitable binders, lubricants and disinte grants as well as dyes can likewise be incorporated into the mixture. Suitable binders include starch, gelatine, natural sugars, such as, for 30 example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. The lubricants used in these dosage forms include sodium oleate, sodium 35 stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The disintegrants include, without being restricted thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like.

WO 2012/052102 PCT/EP2011/004746 - 39 The tablets are formulated by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disinteg rant and pressing the entire mixture to give tablets. A powder mixture is prepared by mixing the compound comminuted in a suitable manner with a 5 diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinyl pyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an 10 absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acadia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve. As an alternative to 15 granulation, the powder mixture can be run through a tabletting machine, giving lumps of non-uniform shape, which are broken up to form granules. The granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets. The compounds 20 according to the invention can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material 25 and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units. Oral liquids, such as, for example, solution, syrups and elixirs, can be pre 30 pared in the form of dosage units so that a given quantity comprises a pre specified amount of the compound. Syrups can be prepared by dissolving the compound in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be for 35 mulated by dispersion of the compound in a non-toxic vehicle. Solubilisers and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, WO 2012/052102 PCT/EP20111/004746 - 40 for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added. The dosage unit formulations for oral administration can, if desired, be encapsulated in microcapsules. The formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like. 10 The compounds of the formula I and salts thereof can also be administered in the form of liposome delivery systems, such as, for exam ple, small unilamellar vesicles, large unilamellar vesicles and multilamellar 15 vesicles. Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines. The compounds of the formula I and the salts thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds can also be coupled to soluble polymers as targeted medicament carriers. Such polymers may encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmeth acrylamidophenol, polyhydroxyethylaspartamidophenol or polyethylene 25 oxide polylysine, substituted by palmitoyl radicals. The compounds may furthermore be coupled to a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, poly 30 orthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels. Pharmaceutical formulations adapted for transdermal administration can be administered as independent plasters for extended, close contact with 35 the epidermis of the recipient. Thus, for example, the active compound can WO 2012/052102 PCT/EP2011/004746 -41 be delivered from the plaster by iontophoresis, as described in general terms in Pharmaceutical Research, 3(6), 318 (1986). Pharmaceutical compounds adapted for topical administration can be for 5 mulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. For the treatment of the eye or other external tissue, for example mouth 10 and skin, the formulations are preferably applied as topical ointment or cream. In the case of formulation to give an ointment, the active compound can be employed either with a paraffinic or a water-miscible cream base. Alternatively, the active compound can be formulated to give a cream with 15 an oil-in-water cream base or a water-in-oil base. Pharmaceutical formulations adapted for topical application to the eye include eye drops, in which the active compound is dissolved or sus 20 pended in a suitable carrier, in particular an aqueous solvent. Pharmaceutical formulations adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes. 25 Pharmaceutical formulations adapted for rectal administration can be administered in the form of suppositories or enemas. Pharmaceutical formulations adapted for nasal administration in which the 30 carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose. 35 Suitable formulations for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil.

WO 2012/052102 PCT/EP2011/004746 -42 Pharmaceutical formulations adapted for administration by inhalation encompass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insuf 5 flators. Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray 10 formulations. Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxi 15 dants, buffers, bacteriostatics and solutes, by means of which the formula tion is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise sus pension media and thickeners. The formulations can be administered in single-dose or multidose containers, for example sealed ampoules and 20 vials, and stored in freeze-dried (lyophilised) state, so that only the addition of the sterile carrier liquid, for example water for injection purposes, imme diately before use is necessary. Injection solutions and suspensions pre pared in accordance with the recipe can be prepared from sterile powders, 25 granules and tablets. It goes without saying that, in addition to the above particularly mentioned constituents, the formulations may also comprise other agents usual in the 30 art with respect to the particular type of formulation; thus, for example, formulations which are suitable for oral administration may comprise fla vours. 35 A therapeutically effective amount of a compound of the formula I depends on a number of factors, including, for example, the age and weight of the animal, the precise condition that requires treatment, and its severity, the WO 2012/052102 PCT/EP2011/004746 -43 nature of the formulation and the method of administration, and is ulti mately determined by the treating doctor or vet. However, an effective amount of a compound according to the invention for the treatment of neo 5 plastic growth, for example colon or breast carcinoma, is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can 10 be administered as a single dose per day or usually in a series of part doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the 15 fraction of the effective amount of the compound according to the invention per se. It can be assumed that similar doses are suitable for the treatment of other conditions mentioned above. 20 The invention furthermore relates to medicaments comprising at least one compound of the formula I and/or pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active compound. 25 The invention also relates to a set (kit) consisting of separate packs of (a) an effective amount of a compound of the formula I and/or pharma ceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios, 30 and (b) an effective amount of a further medicament active compound. The set comprises suitable containers, such as boxes, individual bottles, 35 bags or ampoules. The set may, for example, comprise separate am poules, each containing an effective amount of a compound of the formula WO 2012/052102 PCT/EP20111004746 -44 I and/or pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further medicament active compound in dis solved or lyophilised form. 5 USE The present compounds are suitable as pharmaceutical active 10 compounds for mammals, especially for humans, in the treatment of diseases. The present invention encompasses the compounds of the formula I for use in the treatment or prevention of autoimmune diseases, inflammatory 15 diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, blood platelet aggregation, cancer, sperm motility, transplant rejection, graft rejection and lung injuries. 20 The present invention encompasses the use of the compounds of the formula I and/or physiologically acceptable salts thereof for the preparation of a medicament for the treatment or prevention of autoimmune diseases, 25 inflammatory diseases, cardiovascular diseases, neurodegenerative dis eases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, blood platelet aggregation, cancer, sperm motility, transplant rejection, graft rejection and lung injuries. 30 The compounds according to the invention are preferably used for the pre paration of a medicament for the treatment of a disorder selected from multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, lung inflammation, 35 thrombosis or brain infection or inflammation, such as meningitis or encephalitis, Alzheimer's disease, Huntington's disease, CNS trauma, WO 2012/052102 PCT/EP20111/004746 -45 stroke, or ischaemic states, cardiovascular diseases, such as atherosclerosis, cardiac hypertrophy, cardiac myocyte dysfunction, hypertension or vasoconstriction. 5 The present invention encompasses the use of the compounds of the formula I and/or physiologically acceptable salts thereof for the preparation of a medicament for the treatment or prevention of autoimmune diseases or inflammatory diseases, such as multiple sclerosis, psoriasis, rheumatoid 10 arthritis, systemic lupus erythematosus, inflammatory bowel disease, lung inflammation, thrombosis or brain infection or inflammation, such as meningitis or encephalitis. 15 The present invention encompasses the use of the compounds of the formula I and/or physiologically acceptable salts thereof for the preparation of a medicament for the treatment or prevention of neurodegenerative diseases, such as, inter alia, multiple sclerosis, Alzheimer's disease, 20 Huntington's disease, CNS trauma, stroke or ischaemic states. The present invention encompasses the use of the compounds of the formula I and/or physiologically acceptable salts thereof for the preparation of a medicament for the treatment or prevention of cardiovascular 25 diseases, such as atherosclerosis, cardiac hypertrophy, cardiac myocyte dysfunction, hypertension or vasoconstriction. The present invention encompasses the use of the compounds of the 30 formula I and/or physiologically acceptable salts thereof for the preparation of a medicament for the treatment or prevention of chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke, ischaemic states, ischemia-reperfusion, blood 35 platelet aggregation or activation, skeletal muscle atrophy or hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastasis, in particular melanoma, Karposi's sarcoma, acute and chronic bacterial WO 2012/052102 PCT/EP2011/004746 - 46 and viral infections, sepsis, transplant rejection, graft rejection, glomerulosclerosis, glomerulonephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung, and lung airway inflammation. 5 The present invention encompasses the use of the compounds of the formula I and/or physiologically acceptable salts thereof for the preparation of a medicament for the treatment or prevention of cancer in a mammal, including humans, where the cancer is selected from: brain (gliomas), 10 glioblastomas, leukaemias, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast cancer, inflammatory breast cancer, Wilm's tumour, Ewing's sarcoma, rhabdomyosarcoma, ependymoma, medulloblastoma, colon, head and neck, kidney, lung, liver, 15 melanoma, ovary, pancreas, prostate, sarcoma, osteosarcoma, giant-cell tumour of bone and thyroid. The present invention encompasses the use of the compounds of the 20 formula I and/or physiologically acceptable salts thereof for the preparation of a medicament for the treatment or prevention of cancer in a mammal, including humans, where the cancer is selected from: lymphoblastic T-cell leukaemia, chronic myelogenous leukaemia, chronic lymphocytic leukaemia, hairy-cell leukaemia, acute lymphoblastic leukaemia, acute 25 myelogenous leukaemia, chronic neutrophilic leukaemia, acute lymphoblastic T-cell leukaemia, plasmacytoma, immunoblastic large cell leukaemia, mantle cell leukaemia, multiple myeloma, megakaryoblastic leukaemia, multiple myeloma, acute megakaryocytic leukaemia, 30 promyelocytic leukaemia and erythroleukaemia. The present invention encompasses the use of the compounds of the formula I and/or physiologically acceptable salts thereof for the preparation 35 of a medicament for the treatment or prevention of cancer in a mammal, including humans, where the cancer is selected from malignant lymphoma, WO 2012/052102 PCT/EP2011/004746 - 47.. Hodgkin's lymphoma, non-Hodgkin's lymphoma, lymphoblastic T-cell lymphoma, Burkitt's lymphoma and follicular lymphoma. The invention preferably relates to a method for the treatment of cancer in 5 a mammal, including humans, where the cancer is selected from: neuro blastoma, bladder cancer, urothelial cancer, lung cancer, vulvar cancer, cervical cancer, endometrial cancer, renal cancer, mesothelioma, oesophageal cancer, salivary gland cancer, hepatocellular cancer, bowel cancer, nasopharyngeal cancer, buccal cancer, mouth cancer, GIST 10 (gastrointestinal stromal tumour) and testicular cancer. The compounds of the formula I can furthermore be used in order to provide additive or synergistic effects in certain existing cancer 15 chemotherapies, and/or can be used in order to restore the efficacy of certain existing cancer chemotherapies and radiotherapies. Also encompassed is the use of the compounds of the formula I and/or 20 physiologically acceptable salts thereof for the preparation of a medicament in a mammal, where a therapeutically effective amount of a compound according to the invention is administered. The therapeutic amount varies according to the specific disease and can be determined by the person skilled in the art without undue effort. 25 The disclosed compounds of the formula I can be administered in combi nation with other known therapeutic agents, including anticancer agents. As used here, the term "anticancer agent" relates to any agent which is 30 administered to a patient with cancer for the purposes of treating the can cer. The anti-cancer treatment defined herein may be applied as a sole therapy 35 or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti- tumour agents: WO 2012/052102 PCT/EP2011/004746 - 48- (i) antiproliferative/antineoplastic/DNA-damaging agents and combi nations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, 5 melphalan, chloroambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and gemcitabine); antitumour antibiotics (for example anthracyclines, like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, 10 mitomycin-C, dactinomycin and mithrarnycin) ; antimitotic agents (for example vincan alkaloids, like vincristine, vinblastine, vindesine and vino relbine, and taxoids, like taxol and taxotere) ; topoisomerase inhibitors (for example epipodophyllotoxins, like etoposide and teniposide, amsacrine, 15 topotecan, irinotecan and camptothecin) and cell-differentiating agents (for example all-trans-retinoic acid, 13-cis-retinoic acid and fenretinide); (ii) cytostatic agents, such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptor 20 downregulators (for example fulvestrant), antiandrogens (for example bi calutamide, flutamide, nilutamide and cyproterone acetate), LHRH antago nists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progesterones (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibi 25 tors of 5a-reductase, such as finasteride; (iii) agents which inhibit cancer cell invasion (for example metallo proteinase inhibitors, like marimastat, and inhibitors of urokinase plasmi nogen activator receptor function); 30 (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbb2 antibody trastuzumab [Herceptin T] and the anti erbbl antibody cetuximab [C225]), farnesyl transferase inhibitors, tyrosine 35 kinase inhibitors and serine/threonine kinase inhibitors, for example inhibi tors of the epidermal growth factor family (for example EGFR family tyro- WO 2012/052102 PCT/EP2011/004746 -49 sine kinase inhibitors, such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6 (3-morpholinopropoxy) quinazolin-4-amine (gefitinib, AZD1839), _N-(3 ethynylphenyl)-6,7-bis (2-methoxyethoxy)quinazolin-4-amine (erlotinib, 5 OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholino propoxy)quinazolin-4-amine (Cl 1033) ), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family; (v)antiangiogenic agents, such as those which inhibit the effects of vascu 10 lar endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [AvastinTM], compounds such as those disclosed in published international patent applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and 15 compounds that work by other mechanisms (for example linomide, inhibi tors of integrin avp3 function and angiostatin); (vi) vessel-damaging agents, such as combretastatin A4 and com pounds disclosed in international patent applications WO 99/02166, 20 WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213; (vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-Ras antisense; (viii) gene therapy approaches, including, for example, approaches for 25 replacement of aberrant genes, such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches, such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme, and approaches for increasing patient tolerance to 30 chemotherapy or radiotherapy, such as multi-drug resistance gene ther apy; and (ix) immunotherapy approaches, including, for example, ex-vivo and in-vivo approaches for increasing the immunogenicity of patient tumour 35 cells, such as transfection with cytokines, such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches for WO 2012/052102 PCT/EP2011/004746 - 50 decreasing T-cell anergy, approaches using transfected immune cells, such as cytokine-transfected dendritic cells, approaches using cytokine transfected tumour cell lines, and approaches using anti-idiotypic anti bodies. 5 The medicaments from Table 1 below are preferably, but not exclusively, combined with the compounds of the formula 1. 10 Table 1. Alkylating agents Cyclophosphamide Lomustine Busulfan Procarbazine Ifosfamide Altretamine Melphalan Estramustine phosphate Hexamethylmelamine Mechloroethamine 15 Thiotepa Streptozocin chloroambucil Temozolomide Dacarbazine Semustine Carmustine Platinum agents Cisplatin Carboplatin 20 Oxaliplatin ZD-0473 (AnorMED) Spiroplatin Lobaplatin (Aetema) Carboxyphthalatoplatinum Satraplatin (Johnson Matthe Tetraplatin BBR-3464 (Hoffrnann-La Ormiplatin Roche) lproplatin SM-11355 (Sumitomo) AP-5280 (Access) 25 Antimetabolites Azacytidine Tomudex Gemcitabine Trimetrexate Capecitabine Deoxycoformycin 5-fluorouracil Fludarabine Floxuridine Pentostatin 30 2-chlorodesoxyadenosine Raltitrexed 6-Mercaptopurine Hydroxyurea 6-Thioguanine Decitabine (SuperGen) Cytarabine Clofarabine (Bioenvision) 2-fluorodesoxycytidine Irofulven (MGI Pharrna) Methotrexate DMDC (Hoffmann-La Roche 35_ Idatrexate Ethynylcytidine (Taiho) 35 Topoisomerase Amsacrine Rubitecan (SuperGen) inhibitors Epirubicin Exatecan mesylate (Daiichi) WO 2012/052102 PCT/EP2011/004746 - 51 Etoposide Quinamed (ChemGenex) Teniposide or mitoxantrone Gimatecan (Sigma- Tau) Irinotecan (CPT-1 1) Diflomotecan (Beaufour 7-ethyl-10- Ipsen) hydroxycamptothecin TAS-103 (Taiho) 5 Topotecan Elsamitrucin (Spectrum) Dexrazoxanet (TopoTarget) J-1 07088 (Merck & Co) Pixantrone (Novuspharrna) BNP-1350 (BioNumerik) Rebeccamycin analogue CKD-602 (Chong Kun Dang) (Exelixis) KW-2170 (Kyowa Hakko) BBR-3576 (Novuspharrna) 10 Antitumour antibiot Dactinomycin (Actinomycin [ Amonafide Doxorubicin (Adriamycin) Azonafide Deoxyrubicin Anthrapyrazole Valrubicin Oxantrazole Daunorubicin (Daunomycin) Losoxantrone Epirubicin Bleomycin sulfate (Blenoxan 15 Therarubicin Bleomycinic acid Idarubicin Bleomycin A Rubidazon Bleomycin B Plicamycinp Mitomycin C Porfiromycin MEN-10755 (Menarini) Cyanomorpholinodoxorubicir GPX-100 (Gem 20 Mitoxantron (Novantron) Pharmaceuticals) Antimitotic agents Paclitaxel SB 408075 (GlaxoSmithKlint Docetaxel E701 0 (Abbott) Colchicine PG-TXL (Cell Therapeutics) Vinblastine IDN 5109 (Bayer) Vincristine A 105972 (Abbott) 25 Vinorelbine A 204197 (Abbott) Vindesine LU 223651 (BASF) Dolastatin 10 (NCI) D 24851 (ASTA Medica) Rhizoxin (Fujisawa) ER-86526 (Eisai) Mivobulin (Warner-Lambert) Combretastatin A4 (BMS) Cemadotin (BASF) lsohomohalichondrin-B 30 RPR 109881A (Aventis) (PharmaMar) TXD 258 (Aventis) ZD 6126 (AstraZeneca) Epothilone B (Novartis) PEG-Paclitaxel (Enzon) T 900607 (Tularik) AZ10992 (Asahi) T 138067 (Tularik) !DN-5109 (Indena) Cryptophycin 52 (Eli Lilly) AVLB (Prescient Vinflunine (Fabre) NeuroPharma) 35 Auristatin PE (Teikoku Azaepothilon B (BMS) Hormone) BNP- 7787 (BioNumerik) BMS 247550 BMS) CA-4-prodrug (OXiGENE) WO 2012/052102 PCT/EP2011/004746 - 52 BMS 184476 (BMS) Dolastatin-10 (NrH) BMS 188797 (BMS) CA-4 (OXiGENE) Taxoprexin (Protarga) Aromatase Aminoglutethimide Exemestan 5 inhibitors Letrozole Atamestan (BioMedicines) Anastrazole YM-511 (Yamanouchi) Formestan Thymidylate Pemetrexed (Eli Lilly) Nolatrexed (Eximias) synthase ZD-9331 (BTG) CoFactor T M (BioKeys) 10 inhibitors DNA antagonists Trabectedin (PharmaMar) Mafosfamide (Baxter Glufosfamide (Baxter International) International) Apaziquone (Spectrum Albumin + 32P (Isotope Pharmaceuticals) Solutions) 06-benzylguanine (Paligent) 15 Thymectacin (NewBiotics) Edotreotid (Novartis) Farnesyl transferaE Arglabin (NuOncology Labs) Tipifarnib (Johnson & inhibitors lonafarnib (Schering-Plough) Johnson) BAY-43-9006 (Bayer) Perillyl alcohol (DOR 20 ] BioPharma) Pump inhibitors CBT-1 (CBA Pharma) Zosuquidar trihydrochloride Tariquidar (Xenova) (Eli Lilly) SMS-209 (Schering AG) Biricodar dicitrate (Vertex) Histone Tacedinaline (Pfizer) Pivaloyloxymethyl butyrate 25 acetyl-transferase SAHA (Aton Pharma) (Titan) inhibitors MS-275 (Schering AG) Depsipeptide (Fujisawa) Metalloproteinase Neovastat (Aeterna CMT -3 (CollaGenex) inhibitors Laboratories) BMS-275291 (Celltech) Ribonucleoside Marimastat (British Biotech) Tezacitabine (Aventis) 30 reductase Gallium maltolate (Titan) Didox (Molecules for Health) inhibitors Triapin (Vion) TNF-alpha Virulizin (Lorus Therapeutics Revimid (Celgene) agonists / anta- CDC-394 (Celgene) gonists 35 - WO 2012/052102 PCT/EP2011/004746 - 53.

Endothelin-A Atrasentan (Abbot) YM-598 (Yamanouchi) receptor ZD-4054 (AstraZeneca) antagonists Retinoic acid Fenretinide (Johnson & Alitretinoin (Ligand) 5 receptor agonists Johnson) LGD-1550 (Ligand) ImmunomodulatorE Interferon Dexosome therapy (Anosys) Oncophage (Antigenics) Pentrix (Australian Cancer GMK (Progenics) Technology) 10 Adenocarcinoma vaccine JSF-154 (Tragen) (Biomira) Cancer vaccine (Intercell) CTP-37 (AVI BioPharma) Norelin (Biostar) JRX-2 (lmmuno-Rx) BLP-25 (Biomira) PEP-005 (Peplin Biotech) MGV (Progenics) Synchrovax vaccines (CTL !3-Alethin (Dovetail) Immuno) CLL-Thera (Vasogen) 15 Melanoma vaccine (CTL Immuno) p21-RAS vaccine (GemVa Hormonal and Oestrogens Prednisone antihormonal agen Conjugated oestrogens Methylprednisolone 20 Ethynyloestradiol Prednisolone chlorotrianisene Aminoglutethimide Idenestrol Leuprolide Hydroxyprogesterone caproa Goserelin Medroxyprogesterone Leuporelin Testosterone Bicalutamide Testosterone propionate Flutamide 25 Fluoxymesterone Octreotide Methyltestosterone Nilutamide Diethylstilbestrol Mitotan Megestrol P-04 (Novogen) Tamoxifen 2-Methoxyoestradiol Toremofin (EntreMed) 30 Dexamethasone Arzoxifen (Eli Lilly) Photodynamic Talaporfin (Light Sciences) Pd-Bacteriopheophorbid agents Theralux (Theratechnologies (Yeda) Motexafin-Gadolinium Lutetium-Texaphyrin (Pharmacyclics) (Pharmacyclics) Hypericin 35 Tyrosine kinase Imatinib (Novartis) Kahalide F (PharmaMar) inhibitors Leflunomide CEP- 701 (Cephalon) WO 2012/052102 PCT/EP2011/004746 - 54 (Sugen/Pharmacia) CEP-751 (Cephalon) ZD1839 (AstraZeneca) MLN518 (Millenium) Erlotinib (Oncogene Science, PKC412 (Novartis) Canertjnib (Pfizer) Phenoxodiol 0 Squalamine (Genaera) Trastuzumab (Genentech) 5 SU5416 (Pharmacia) C225 (ImClone) SU6668 (Pharmacia) rhu-Mab (Genentech) ZD4190 (AstraZeneca) MDX-H210 (Medarex) ZD6474 (AstraZeneca) 2C4 (Genentech) Vatalanib (Novartis) MDX-447 (Medarex) PKI166 (Novartis) ABX-EGF (Abgenix) GW2016 (GlaxoSmithKline) IMC-1C11 (ImClone) 10 EKB-509 (Wyeth) EKB-569 (Wyeth) Various agents SR-27897 (CCK-A inhibitor, BCX-1777 (PNP inhibitor, Sanofi-Synthelabo) BioCryst) Tocladesine (cyclic AMP Ranpirnase (ribonuclease agonist, Ribapharm) stimulant, Alfacell) 15 Alvocidib (CDK inhibitor, Galarubicin (RNA synthesis Aventis) inhibitor, Dong-A) CV-247 (COX-2 inhibitor, Ivy Tirapazamine Medical) (reducing agent, SRI P54 (COX-2 inhibitor, International) Phytopharm) N-Acetylcysta (reducing 20 CapCelI T M (CYP450 agent, Zambon) stimulant, Bavarian Nordic) R-Flurbiprofen (NF-kappaB GCS-iO (gal3 antagonist, inhibitor, Encore) GlycoGenesys) 3CPA (NF-kappaB inhibitor, G17DT immunogen (gastrin Active Biotech) inhibitor, Aphton) Seocalcitol (vitamin D Efaproxiral (oxygenator, Allo receptor agonist, Leo) 25 Therapeutics) 131-1-TM-601 (DNA PI-88 (heparanase inhibitor, antagonist, TransMolecular) Progen) Eflornithin (ODC inhibitor, Tesmilifen (histamine ILEX Oncology) antagonist, YM BioSciences) Minodronic acid (osteoclast Histamine (histamine H2 inhibitor, Yamanouchi) receptor agonist, Maxim) Indisulam (p53 stimulant, 30 Tiazofurin (lMPDH inhibitor, Eisai) Ribapharm) Aplidin (PPT inhibitor, Cilengitide (integrin antagoni: PharmaMar) Merck KGaA) Rituximab (CD20 antibody, SR-31747 (IL-1 antagonist, Genentech) Sanofi-Synthelabo) Gemtuzumab (CD33 35 CCI-779 (mTOR kinase antibody, Wyeth Ayerst) inhibitor, Wyeth) PG2 (haematopoiesis Exisulind (PDE-V inhibitor, promoter, Pharmagenesis) WO 2012/052102 PCT/EP2011/004746 -55 Cell Pathways) Immunol TM (triclosan CP-461 (PDE-V inhibitor, Cel mouthwash, Endo) Pathways) Triacetyluridine (uridine prod AG-2037 (GART inhibitor, Wellstat) Pfizer) SN-4071 (sarcoma agent, 5 WX-UK1 Signature BioScience) (plasminogen activator TransMID-107 TM inhibitor, Wilex) (immunotoxin, KS Biomedix) PBI-1402 (PMN stimulant, PCK-3145 (apoptosis ProMetic LifeSciences) promoter, Procyon) Bortezomib (proteasome Doranidazole (apoptosis inhibitor, Millennium) promoter, Pola) 10 SRL-172 (T-cell stimulant, CHS-828 (cytotoxic SR Pharma) agent, Leo) TLK-286 (glutathione-S trans-Retinoic acid transferase inhibitor, Telik) (differentiator, NIH) PT-1 00 (growth factor MX6 (apoptosis promoter, agonist, Point Therapeutics) MAXIA) 15 Midostaurin (PKC inhibitor, Apomine (apoptosis promotE Novartis) ILEX Oncology) Bryostatin-1 (PKC stimulant, Urocidin (apoptosis promote GPC Biotech) Bioniche) CDA-Il (apoptosis promoter, Ro-31-7453 (apoptosis Everlife) promoter, La Roche) SDX-101 (apoptosis promote Brostallicin (apoptosis 20 Salmedix) promoter, Pharmacia) Ceflatonin (apoptosis promoter, ChemGenex) Alkylating agents Cyclophosphamide Lomustine Busulfan Procarbazine 25 Ifosfamide Altretamine Melphalan Estramustine phosphate Hexamethylmelamine Mechloroethamine Thiotepa Streptozocin chloroambucil Temozolomide Dacarbazine Semustine Carmustine Platinum agents Cisplatin Carboplatin Oxaliplatin ZD-0473 (AnorMED) Spiroplatin Lobaplatin (Aetema) Carboxyphthalatoplatin um Satraplatin (Johnson Matthey Tetraplatin BBR-3464 (Hoffrnann-La 35 Ormiplatin Roche) lproplatin SM-1 1355 (Sumitomo) AP-5280 (Access) WO 2012/052102 PCT/EP2011/004746 - 56 Antimetabolites Azacytidine Tomudex Gemcitabine Trimetrexate Capecitabine Deoxycoformycin 5-fluorouracil Fludarabine 5 Floxuridine Pentostatin 2-chlorodesoxyadenosine Raltitrexed 6-Mercaptopurine Hydroxyurea 6-Thioguanine Decitabine (SuperGen) Cytarabine Clofarabine (Bioenvision) 2-fluorodesoxycytidine Irofulven (MGI Pharrna) Methotrexate DMDC (Hoffmann-La Roche) 10 __ Idatrexate Ethynylcytidine (Taiho) Topoisomerase Amsacrine Rubitecan (SuperGen) inhibitors Epirubicin Exatecan mesylate (Daiichi) Etoposide Quinamed (ChemGenex) Teniposide or mitoxantrone Gimatecan (Sigma- Tau) 15 Irinotecan (CPT-11) Diflomotecan (Beaufour 7-ethyl-10- Ipsen) hydroxycamptothecin TAS-103 (Taiho) Topotecan Elsamitrucin (Spectrum) Dexrazoxanet (TopoTarget) J-1 07088 (Merck & Go) Pixantrone (Novuspharrna) BNP-1350 (BioNumerik) 20 Rebeccamycin analogue CKD-602 (Chong Kun Dang) (Exelixis) KW-2170 (Kyowa Hakko) BBR-3576 (Novuspharrna) Antitumour antibiot Dactinomycin (Actinomycin Amonafide Doxorubicin (Adriamycin) Azonafide Deoxyrubicin Anthrapyrazole 25 Valrubicin Oxantrazole Daunorubicin (Daunomycin) Losoxantrone Epirubicin Bleomycin sulfate (Blenoxan) Therarubicin Bleomycinic acid Idarubicin Bleomycin A Rubidazon Bleomycin B 30 Plicamycinp Mitomycin C Porfiromycin MEN-10755 (Menarini) Cyanomorpholinodoxorubici GPX-100 (Gem Mitoxantron (Novantron) Pharmaceuticals) Antimitotic agents Paclitaxel SB 408075 (GlaxoSmith Kline Docetaxel E7010 (Abbott) 35 Colchicine PG-TXL (Cell Therapeutics) Vinblastine IDN 5109 (Bayer) Vincristine A 105972 (Abbott) WO 2012/052102 PCT/EP2011/004746 - 57 Vinorelbine A 204197 (Abbott) Vindesine LU 223651 (BASF) Dolastatin 10 (NCI) D 24851 (ASTA Medica) Rhizoxin (Fujisawa) ER-86526 (Eisai) Mivobulin (Warner-Lambert Combretastatin A4 (BMS) 5 Cemadotin (BASF) lsohomohalichondrin-B RPR 109881A (Aventis) (PharmaMar) TXD 258 (Aventis) ZD 6126 (AstraZeneca) Epothilone B (Novartis) PEG-Paclitaxel (Enzon) T 900607 (Tularik) AZ10992 (Asahi) T 138067 (Tularik) !DN-5109 (Indena) Cryptophycin 52 (Eli Lilly) AVLB (Prescient 10 Vinflunine (Fabre) NeuroPharma) Auristatin PE (Teikoku Azaepothilon B (BMS) Hormone) BNP- 7787 (BioNumerik) BMS 247550 (BMS) CA-4-prodrug (OXiGENE) BMS 184476 (BMS) Dolastatin-10 (NrH) BMS 188797 (BMS) CA-4 (OXiGENE) 15 Taxoprexin (Protarga) Aromatase Aminoglutethimide Exemestan inhibitors Letrozole Atamestan (BioMedicines) Anastrazole YM-511 (Yamanouchi) Formestan 20 Thymidylate Pemetrexed (Eli Lilly) Nolatrexed (Eximias) synthase ZD-9331 (BTG) CoFactorTM (BioKeys) inhibitors DNA antagonists Trabectedin (PharmaMar) Mafosfamide (Baxter Glufosfamide (Baxter International) 25 International) Apaziquone (Spectrum Albumin + 32P (Isotope Pharmaceuticals) Solutions) 06-benzylguanine (Paligent) Thymectacin (NewBiotics) Edotreotid Novartis) 30 lFarnesyl transfer Arglabin (NuOncology Labs Tipifarnib (Johnson & inhibitors lonafarnib (Schering-Plough Johnson) BAY-43-9006 (Bayer) Perillyl alcohol (DOR BioPharma) Pump inhibitors CBT-1 (CBA Pharma) Zosuquidar trihydrochloride Tariquidar (Xenova) (Eli Lilly) 35 _MS-209 (Scherin AG Biricodar dicitrate (Vertex WO 2012/052102 PCT/EP2011/004746 -58 Histone Tacedinaline (Pfizer) Pivaloyloxymethyl butyrate acetyl-transferase SAHA (Aton Pharma) (Titan) inhibitors MS-275 Schering AG) Depsipeptide (Fujisawa) Metalloproteinase Neovastat (Aeterna CMT -3 (CollaGenex) 5 inhibitors Laboratories) BMS-275291 (Celltech) Ribonucleoside Marimastat (British Biotech) Tezacitabine (Aventis) reductase Gallium maltolate (Titan) Didox (Molecules for Health) inhibitors Triapin (Vion) TNF-alpha Virulizin (Lorus Therapeutic Revimid (Celgene) 10 agonists/antagoni- CDC-394 (Celgene) sts Endothelin-A Atrasentan (Abbot) YM-598 (Yamanouchi) receptor ZD-4054 (AstraZeneca) antagonists 15 Retinoic acid Fenretinide (Johnson & Alitretinoin (Ligand) receptor agonists Johnson) LGD-1 550 (Ligand) Immunomod ulatorr Interferon Dexosome therapy (Anosys) Oncophage (Antigenics) Pentrix (Australian Cancer 20 GMK (Progenics) Technology) Adenocarcinoma vaccine JSF-154 (Tragen) (Biomira) Cancer vaccine (Intercell) CTP-37 (AVI BioPharma) Norelin (Biostar) JRX-2 (Immuno-Rx) BLP-25 (Biomira) PEP-005 (Peplin Biotech) MGV (Progenics) Synchrovax vaccines (CTL !3-Alethin (Dovetail) 25 Immuno) CLL-Thera (Vasogen) Melanoma vaccine (CTL Immuno) p21-RAS vaccine (GemVa Hormonal and Oestrogens Prednisone 30 antihormonal agen Conjugated oestrogens Methylprednisolone Ethynyloestradiol Prednisolone chlorotrianisene Aminoglutethimide Idenestrol Leuprolide Hydroxyprogesterone capro Goserelin Medroxyprogesterone Leuporelin Testosterone Bicalutamide 35 Testosterone propionate Flutamide Fluoxymesterone Octreotide Methyltestosterone Nilutamide WO 2012/052102 PCT/EP2011/004746 - 59.

Diethylstilbestrol Mitotan Megestrol P-04 (Novogen) Tamoxifen 2-Methoxyoestradiol Toremofin (EntreMed) Dexamethasone Arzoxifen (Eli Lilly) 5 Photodynamic Talaporfin (Light Sciences) Pd-Bacteriopheophorbid agents Theralux (Theratechnologie (Yeda) Motexafin-Gadolinium Lutetium-Texaphyrin (Pharmacyclics) (Pharmacyclics) Hypericin 10 Tyrosine kinase Imatinib (Novartis) Kahalide F (PharmaMar) inhibitors Leflunomide CEP- 701 (Cephalon) (Sugen/Pharmacia) CEP-751 (Cephalon) ZD1839 (AstraZeneca) MLN518 (Millenium) Erlotinib (Oncogene Scienc PKC412 (Novartis) Canertjnib (Pfizer) Phenoxodiol 0 15 Squalamine (Genaera) Trastuzumab (Genentech) SU5416 (Pharmacia) C225 (ImClone) SU6668 (Pharmacia) rhu-Mab (Genentech) ZD4190 (AstraZeneca) MDX-H210 (Medarex) ZD6474 (AstraZeneca) 2C4 (Genentech) Vatalanib (Novartis) MDX-447 (Medarex) 20 PKI166 (Novartis) ABX-EGF (Abgenix) GW2016 (GlaxoSmithKline) IMC-1C11 (ImClone) EKB-509 (Wyeth) EKB-569 (Wyeth) Various agents SR-27897 (CCK-A inhibitor, BCX-1777 (PNP inhibitor, Sanofi-Synthelabo) BioCryst) Tocladesine (cyclic AMP Ranpirnase (ribonuclease 25 agonist, Ribapharm) stimulant, Alfacell) Alvocidib (CDK inhibitor, Galarubicin (RNA synthesis Aventis) inhibitor, Dong-A) CV-247 (COX-2 inhibitor, Iv, Tirapazamine (reducing agen Medical) SRI International) P54 (COX-2 inhibitor, N-Acetylcysta 30 Phytopharm) (reducing agent, Zambon) CapCelITM (CYP450 R-Flurbiprofen (NF-kappaB stimulant, Bavarian Nordic) inhibitor, Encore) GCS-OO (gal3 antagonist, 3CPA (NF-kappaB inhibitor, GlycoGenesys) Active Biotech) G17DT immunogen (gastrin Seocalcitol (vitamin D inhibitor, Aphton) receptor agonist, Leo) 35 Efaproxiral (oxygenator, All< 131-1-TM-601 (DNA Therapeutics) antagonist, TransMolecular) PI-88 (hearanase inhibitor, Eflornithin (ODC inhibitor, ILE WO 2012/052102 PCT/EP2011/004746 -60 Progen) Oncology) Tesmilifen (histamine Minodronic acid (osteoclast antagonist, YM BioSciences inhibitor, Yamanouchi) Histamine (histamine H2 Indisulam (p53 stimulant, receptor agonist, Maxim) Eisai) 5 Tiazofurin (IMPDH inhibitor, Aplidin (PPT inhibitor, Ribapharm) PharmaMar) Cilengitide (integrin Rituximab (CD20 antibody, antagonist, Merck KGaA) Genentech) SR-31747 (IL-1 antagonist, Gemtuzumab (CD33 Sanofi-Synthelabo) antibody, Wyeth Ayerst) CCI-779 (mTOR kinase PG2 (haematopoiesis 10 inhibitor, Wyeth) promoter, Pharmagenesis) Exisulind (PDE-V inhibitor, Immunol TM (triclosan Cell Pathways) mouthwash, Endo) CP-461 (PDE-V inhibitor, C Triacetyluridine (uridine prodr Pathways) Wellstat) AG-2037 (GART inhibitor, SN-4071 (sarcoma agent, 15 Pfizer) Signature BioScience) WX-UK1 TransMID-107TM (plasminogen activator (immunotoxin, KS Biomedix) inhibitor, Wilex) PCK-3145 (apoptosis promot PBI-1402 (PMN stimulant, Procyon) ProMetic LifeSciences) Doranidazole (apoptosis Bortezomib (proteasome promoter, Pola) 20 inhibitor, Millennium) CHS-828 (cytotoxic SRL-172 (T-cell stimulant, agent, Leo) SR Pharma) trans-Retinoic acid TLK-286 (glutathione-S (differentiator, NIH) transferase inhibitor, Telik) MX6 (apoptosis promoter, PT-100 (growth factor MAXIA) 25 agonist, Point Therapeutics: Apomine (apoptosis promoter Midostaurin (PKC inhibitor, ILEX Oncology) Novartis) Urocidin (apoptosis promoter, Bryostatin-1 (PKC stimulant Bioniche) GPC Biotech) Ro-31-7453 (apoptosis CDA-Il (apoptosis promoter promoter, La Roche) Everlife) Brostallicin (apoptosis 30 SDX-101 (apoptosis promoter, Pharmacia) promoter, Salmedix) Ceflatonin (apoptosis promoter, ChemGenex) 35 A combined treatment of this type can be achieved with the aid of simulta neous, consecutive or separate dispensing of the individual components of WO 2012/052102 PCT/EP2011/004746 - 61 the treatment. Combination products of this type employ the compounds according to the invention. ASSAYS 5 The compounds of the formula I described in the examples were tested in the assays described below, and it was found that they have a kinase-in hibiting activity. Other assays are known from the literature and could read 10 ily be performed by the person skilled in the art (see, for example, Dhana bal et al., Cancer Res. 59:189-197; Xin et al., J. Biol Chem. 274:9116 9121; Sheu et al., Anticancer Res. 18:4435-4441; Ausprunk et al., Dev. Biol 38:237-248; Gimbrone et al., J. Natl. Cancer Inst. 52:413-427; Nicosia et al., In Vitro 18:538- 549). 15 Description of the method for the cellular testing of P13K inhibitors The measure used for the cellular P13K activity is the P13K-dependent 20 phosphorylation of PKB at Serin 473. The cellular assay for determination of the P-S473-PKB level is carried out as a Luminex assay in 96-well format in PC3 cells. PC3 cells exhibit constitutive phosphorylation of PKB owing to a PTEN mutation. PC3 cells are sown out with 20,000 cells per well in 100 pl medium (45% 25 RPMI1460 / 45% Ham's F12 /10% FCS) and incubated on the following day for 30 min with a serial dilution of the test substance (7 concentrations) under serum-free conditions. The cells are subsequently lysed using 90 pl of lysis buffer (20 mM Tris/HCI pH 8.0, 150 mM NaCl, 1% NP40, 10% 30 glycerol, 1% phosphatase inhibitor 1, 1% phosphatase inhibitor II, 0.1% protease inhibitor cocktail Ill, 0.01% benzonase) per well, and the lysates are separated off from insoluble cell constituents by means of centrifugation through a 96-well filter plate (0.65 pm). The lysates are 35 incubated overnight at 4"C with shaking with Luminex beads to which an anti-total PKB antibody is coupled. The detection is carried out on the WO 2012/052102 PCT/EP2011/004746 - 62 following day by addition of a P-S473-PKB antibody and a species-specific PE-labelled secondary antibody. The detection of P-S473-PKB is carried out by measurement in a Luminex100 instrument by determination of 100 5 events per cavity in a measurement time of 60 sec. As pharmacological blank, the signals obtained from cells which have been treated with 3 pM wortmannin are subtracted from all other preparations. The control value used for maximum phosphorylation of PKB at S473 are the signals from cells which have been treated only with the solvent (0.3% DMSO). The 10 values of the preparations treated with test substance are calculated from this as per cent of control, and IC50 values are determined by means of RS1. 15 Above and below, all temperatures are indicated in *C. In the following exam ples, "conventional work-up" means: water is added if necessary, the pH is adjusted, if necessary, to values between 2 and 10, depending on the consti tution of the end product, the mixture is extracted with ethyl acetate or 20 dichloromethane, the phases are separated, the organic phase is dried over sodium sulfate, evaporated and purified by chromatography on silica gel and/or by crystallisation. Rf values on silica gel; eluent: ethyl acetate/ metha nol 9:1. 25 Mass spectrometry (MS): El (electron impact ionisation) M* FAB (fast atom bombardment) (M+H)* ESI (electrospray ionisation) (M+H)* APCI-MS (atmospheric pressure chemical ionisation - mass spectrometry) 30 (M+H)*. HPLC-MS: Agilent 1200 series instrument 35 HPLC-MS Esil.Rod.m / Polar.m / Nonpolar.m methods WO 2012/052102 PCT/EP2011/004746 -63 Column Chromolith Speed Rod RP 18e 50-4.6 mm Flow rate 2.4 mi/min Buffer A 0.05% of formic acid / water Buffer B 0.04% of formic acid / acetonitrile Wavelength : 220 nm 5 Gradient : 0.0-2.8 min 4%-100% of buffer B; 2.8-3.3min 100% of Polar-m buffer B; 3.3-3.4 min 100%-4 LC-MS method: polar: 10 Column: Chromolith Speed Rod RP 18e 50-4.6 mm LCMS Polar.m, 2.4 ml/min, 220 nm, buffer A 0.05% of HCOOH/H 2 0, buffer B 0.04% of HCOOH/ACN, 0.0-3.0 min 5%-100% of buffer B; 3.0-3.5 min 100% of buffer B Polar 1: Agilent 1200 series instrument 15 Polar 2: Agilent 1100 series instrument Retention time Rf in minutes [min]. 20 The compounds according to the invention can be prepared by the following synthesis sequences (AAVI and AAV2): AAV method 1: 25

NH

2 OSO R

K

2

CO

3 , dimethylacetamide 50-1500C N Cl 3 0 min - 10 hours N Ci N CI microwave or x I thermally N NH o=s=o R 35 1 equivalent of the sulfonamide or of the alkali-metal salt of the sulfonamide are stirred with 0.9-1.5 equivalents of 2

,

3 -dichloroquinoxaline in a reaction flask with reflux condenser in the presence of 0.1-3 equivalents of an alkali- WO 2012/052102 PCT/EP2011/004746 - 64 metal or alkaline-earth metal carbonate in DMA at temperatures between 30"C and 1 80C with exclusion of water, preferably under protective gas, until the sulfonamide has reacted virtually completely (about 0.5-12 hours). The cooled reaction mixture is added to water and filtered off with suction. The 5 filtrate is acidified, cooled, and the newly formed precipitate is filtered off with suction, rinsed with suitable solvents and dried. If necessary, this can be followed by purification methods known to the person skilled in the art, such as, for example, recrystallisations or chromatographies. 10 AAV method 2: (general procedure) RI 15 R2 I R1

NH

2 0 propanol j R2 50-150 0 C N Cl 30 min - 30 hours N NH 20 N" NH microwave or I thermally N1NH o=S=0s RR 25 1 equivalent of the quinoxaline derivative, 0.9-2.5 equivalents of the amine in 30-100 equivalents of 1-propanol or a comparable alcohol (1-butanol, 2 propanol, ethanol, etc.) or another organic solvent, such as ethyl glycol, dioxane, THF, are heated in a microwave-suitable glass vessel at 40 180*C with high absorption in the microwave until the quinoxaline 30 derivative has reacted virtually completely (about 1-12 hours). The cooled reaction mixture is filtered off with suction, rinsed with 1-propanol and dried. If necessary, this can be followed by purification methods known to the person skilled in the art, such as, for example, recrystallisations or 35 chromatographies.

WO 2012/052102 PCT/EP2011/004746 - 65 This method may in addition be followed by further synthesis steps, which are explained in the examples. 5 The sulfonamides required for the first step are either commercially available or can be prepared by methods known to the person skilled in the art, for example by aminolysis from the corresponding sulfonyl chlorides. 10 Example I Preparation of 1-methyl-1 H-pyrazole-3-sulfonic acid (3-chloroquinoxalin-2 yl) amide (building block for the preparation of A24) 15 HN/0 N Ci

H

2 N, /I 2 KOH, N C1 1) O N-N subsequently N NH yophilise a NICI OS=O N Cl 20 2) DMA, K2CO, 130*C N N6 3) Water, citric acid 2.0 g of 1-methyl-i H-pyrazole-3-sulfonamide and 812 mg of KOH (content 25 84%, remainder water) are stirred in about 20 ml of water in a flask until a clear solution has formed. This is lyophilised for complete removal of the water. The solid potassium salt is heated with 2.74g of 2,3-dichloroquin oxaline and 866 mg of potassium carbonate in about 20 ml of dried DMA 30 under nitrogen at 120*C (bath temperature) until the sulfonamide has reacted virtually completely (HPLC check, about 3 hours). The cooled reaction solution is poured into about 200 ml of ice-water, with a precipitate depositing after some time. This is filtered off with suction and discarded. The filtrate is adjusted to pH 4-5 using saturated citric acid solution. A 35 further precipitate deposits, which is filtered off, washed with water and dried, giving 3.36 g of I-methyl-1 H-pyrazole-3-sulfonic acid (3- WO 2012/052102 PCT/EP2011/004746 -66 chloroquinoxalin-2-yl) amide as pale-beige solid (yield 86%, content 97%). MS-FAB (M+H*) = 324.0. Rf (polar method): 1.85 min. This is employed without further purification for the next step. 5 A similar procedure enables numerous other sulfonamides to be converted into corresponding quinoxaline derivatives: prior separate preparation of the potassium salts is not absolutely necessary, but in some cases results in better yields. If the preparation of the potassium salt is omitted, the 10 corresponding amount of potassium carbonate must be increased to 0.9 2.5 equivalents. Instead of potassium carbonate, it is also possible to employ other alkali-metal or alkaline-earth metal carbonates taking into account the base equivalents). 15 Example 2 Preparation of 2

-[

3

-(

3 -chloroquinoxalin-2-ylsulfamoyl)pyrazol-1-yl]-2,2 difluoro-N,N-dimethylacetamide (building block for the preparation of 20 A119) 1.) DMA, K 2 C0 3 , 140*C O N C1 NH2 H _ N 25 HN- N- N NH 0 0 N N N F F O=S=O F N + F / 2.) Water, then citric acid F N 30 F N 00 \ 1.30 g of 2,2-difluoro-N,N-dimethyl-2-(3-sulfamoylpyrazol-1-yl)acetamide, 35 1.16 g of 2 ,3-dichloroquinoxaline and 670 mg of potassium carbonate in about 16 ml of dried DMA are heated at 100"C (bath temperature) under WO 2012/052102 PCT/EP2011/004746 - 67 nitrogen in a flask until the sulfonamide has reacted virtually completely (HPLC check, about 3 hours). The cooled reaction solution is poured into about 200 ml of ice-water, with a precipitate depositing after some time. 5 This is filtered off with suction and discarded. The filtrate is adjusted to pH 4-5 using saturated citric acid solution. A further precipitate deposits, which is filtered off, washed with water and dried, giving 1.44 g of 2-[3-(3 chloroquinoxalin-2-ylsulfamoyl)pyrazol-1-yl]-2,2-difluoro-N,N dimethylacetamide as pale-beige solid (yield 69%, content 99.8%). MS 10 FAB (M+H*) = 431.0. Rf (polar method): 1.98 min. This is employed without further purification for the next step. The following can be employed, for example (without restricting the 15 process thereto)

NH

2 NH 2 NH 2 0S=O O=S=O 0=s=o 20 N etc. /||0 NN II 0 N6 N 25 Example 3 Preparation of 2,2-difluoro-2-(3-{3-[2-(3-hydroxybutoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-ylsulfamoyl}pyrazol- -yl)-N, N-dimethylacetamide 30 ("A118") 35 WO 2012/052102 PCT/EP2011/004746 -68 N CI OH 0 :""OH N NH N NH 5 F N NH2+ NO NO 0 1 F+ _ H N NHU F NF NN 10 N0F F / _N O 300 mg of 2-[3-(3-chloroquinoxalin-2-ylsulfamoyl)pyrazol-1-yl]-2,2-difluoro N,N-dimethylacetamide and 258 mg of 4-(2-amino-4,6 15 dimethoxyphenoxy)butan-2-ol in 4ml of 1-propanol are heated at 140*C in a microwave-suitable glass vessel with high absorption in the microwave until starting material 1 has reacted virtually completely (about 45 minutes). The cooled reaction mixture is filtered off with suction, rinsed with 1 20 propanol and dried, giving 320 mg of 2,2-difluoro-2-(3-{3-[2-(3 hydroxybutoxy)-3,5-dimethoxyphenylamino]quinoxalin-2-ylsulfamoyl} pyrazol-1-yl)-N,N-dimethylacetamide as slightly yellowish solid (yield 74%). MS-FAB (M+H) = 636.2. Rf (polar method): 2.41 min. 25 Compounds AI-A22, A24-A37, A39-A56, A58-A92, A93-A1 05, A107, A107, A112-A115, A117-A128 and A131 are obtained by this method from the corresponding quinoxaline derivatives and amines: 30 Compound Name and/or structure HPLC MS-FAB No. R [min] / [M+H]+ method 35 WO 2012/052102 PCT/EP2011/004746 -69 "Al" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(6- 2.24 / 455.46 methoxybenzo-1,3-dioxol-4-ylamino)quinoxalin-2- polar 1 yl] amide 5 N N N O O IR S N N N 0 0 10 "A2" 4-Cyano-N-{3-[2-(3-dimethylaminopropyl)-3,5- 1.83 / 547.64 dimethoxyphenylamino]quinoxalin-2-yl}- polar 1 benzenesulfonamide 15 N N N0 O ss N H H N F 200 -A 20 N "A3 4-Cyano-N-(3-{2-[3-(1,1 -dioxo-1 -lambda*6*- 2.15 / 637.75 thiomorpholin-4-yl)propyl]-3,5-dimethoxy- polar 1 phenylamino}quinoxalin-2-yl)benzenesufonamide 25 N>K AN 0 WEE ' S-N N a ll H H / 00 o /--\ 0 S~ N/ 30 0 ,S 35 WO 2012/052102 PCT/EP2011/004746 -70 A4" 1-Methyl-1 H-imidazole-4-sulfonic acid (3-{2-[3- 1.86 / 616.73 (1,1-dioxo-1 -lambda*6*-th iomorphon-4-yl)propyl]- polar 1 3,5-dimethoxyphenylaminoquinoxalin-2-y) amide 0 0 5 N N N NN NH(N O 0 0 10N O /N "A5" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(2- 2.07 / 483.51 hydroxymethyl-5-methoxy-2,3-dihydrobenzofuran- polar 1 7-ylamino)quinoxalin-2-yl] amide 15 N N N o H NH H 20 N N HO 'H NMR (500 MHz, DMSO-d 6 + TFA-d,): 6 [ppm] 8.58 (s, 1H), 8.23 (d, J = 1.3 Hz, 1H), 8.08 (d, J = 2.2 Hz, 1 H), 7.90 (dd, J = 1.8, 7.6 Hz, I H), 25 7.70 (dd, J = 2.2, 7.1 Hz, IH), 7.48 - 7.41 (m, 2H), 6.66 (d, J = 2.5 Hz, 1H), 4.98 - 4.91 (m, 1 H), 3.84 (s, 3H), 3.79 (s, 3H), 3.70 (dd, J = 3.8, 12.0 Hz, 1H), 3.62 (dd, J= 5.4, 12.1 Hz, 1H), 3.28 (dd, J= 9.5, 15.5 Hz, 1H), 3.11 (dd, J = 7.4, 16.0 Hz, 1H) 30 35 WO 2012/052102 PCT/EP2011/004746 -71 "A6" 4-Cyano-N-{3-[2-(4-hydroxybutyl)-3,5-dimethoxy- 2.44 / 534.60 phenylamino]quinoxalin-2-yl}benzenesulfonamide polar 1 A0 5 N NW N 0 0- NH OH 10 "AT 1-Methyl-I H-imidazole-4-sulfonic acid {3-[2-(4- 2.18/ 513.58 hydroxybutyl)-3,5-dimethoxyphenylamino]- polar 1 quinoxalin-2-yl} amide 0 15 N N O ON NH -- N -N 0 20 OH 20 0 "A8" 4-[3-(7-Methoxy-2,3-dihydrobenzo-1,4-dioxin-5- 2.47 / 535.6 ylamino)quinoxalin.-2-ylsulfamoyl]-N, N-dimethyl- polar 1 benzamide 25 0 0 N NH ANXNH 30 0 0 35 WO 2012/052102 PCT/EP2011/004746 -72 "A9" 5-Methoxy-7-[3-(1 -methyl-1 H-imidazole-4- 2.21 / 522.55 sulfonylamino)quinoxalin-2-ylamino]benzofuran-2- polar 1 carboxylic acid dimethyl amide 5 0 O N N) N / 0 NH H -N 0 -N 10 \N "Al 0" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(7- 2.37 / 469.49 methoxy-2,3-dihydrobenzo-1,4-dioxin-5-ylamino)- polar 1 quinoxalin-2-yl] amide 15 7 0 o NH N

N

20 "Al 1" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(2,5- 2.47 / 455.50 dimethoxy-3-methylphenylamino)quinoxalin-2-yl] polar 1 amide 25 O N N H H N N-S ON \ 00 O 0 N N 30 35 WO 2012/052102 PCT/EP2011/004746 -73 "Al 2" 4-[3-(2,5-Dimethoxy-3-methylphenylamino)- 2.57 / 522.6 quinoxalin-2-ylsulfamoyl]-N,N-dimethylbenzamide polar I 0 5 N / N NH N O I' H 1"Al 3" 4 -[3-(2-Ethyl-3,5-dimethoxyphenylamino)- 2.57 536.6 quinoxalin-2-ylsulfamoy]-N, N-dimethylbenzamide 0 H HP - N N N_ 150 0 15 N H \\ "A14" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(2-ethyl- 2.46 469.5 20 3 ,5-dimethoxyphenylamino)quinoxalin-2-y] amide 0 H H /09N 2\ N NS O N N 25 "A15" 4 -1 3 -(5-Methoxybenzofuran-7-ylamino)quinoxalin- 2.35 518.6 2-ylsulfamoyl]-N,N-dimethylbenzamide 30 0 NH 3N 0 H O 35 \I N WO 2012/052102 PCT/EP2011/004746 -74 "Al 6" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(5- 2.25 / 451.6 methoxybenzofuran-7-ylamino)quinoxalin-2-yl] polar 2 amide "A17" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(3-ethyl- 1.76 / 469.5"A1 5 2,5-dimethoxyphenylamino)quinoxalin-2-yl] amide polar I 0 / H ~ H , N O N ON N 10 / "Al 8" 4-[3-(3-Ethyl-2,5-dimethoxyphenylamino)- 2.53 / 536.6 quinoxalin-2-ylsulfamoy]-NN-dimethylbenzamide polar 2 15 / 0 /\H H N N 0 N N 0 20 "Al 9" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(2- 2.37 / 520.4 bromo-3,5-dimethoxyphenylamino)quinoxalin-2-y] polar 1 amide 25 0 Br NH N N- N 30 N H 0 35 WO 2012/052102 PCT/EP2011/004746 -75 "A20" 1-Methyl-1H-imidazole-4-sulfonic acid [3-(2-chloro- 2.35 / 475.9 3,5-dimethoxyphenylamino)quinoxalin-2-yl] amide polar 1 0 5 0 /Cl NH N- 0 N - / ~NN N 0 10 "A21" Pyridine-4-sulfonic acid {3-[2-(3-hydroxypropoxy)- 2.19/ 512.6 3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide polar 1 0 15 0 NH NS N O N 20 "A22" Thiazole-5-sulfonic acid {3-[2-(3-hydroxypropoxy)- 2.28 / 518.58 3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide polar 1 0 0 NHH 25 N N, S N O N 30 35 WO 2012/052102 PCT/EP2011/004746 -76 "A24" 1-Methyl-1 H-pyrazole-3-sulfonic acid {3-[2-(3- 2.27 / 515.1 hydroxypropoxy)-3,5-dimethoxyphenylamino]- polar quinoxalin-2-yl} amide 5 N N 0 \S-N N- 0 0 0 10 HO "A25" N-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxy- 2.21 / 449.49 phenylamino]quinoxalin-2-yl}methanesulfonamide polar 1 151 15 N ",_ N NH O -o 20 "A26" N-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxy- 2.48 / 541.59 phenylamino]quinoxalin-2-yl}-2-methoxy- polar 1 benzenesulfonamide 25 0 N O~ N N 0 30 CC OH 35 WO 2012/052102 PCT/EP2011/004746 -77 "A27" 2-(4-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxy- 2.14 / 586.63 phenylamino]quinoxaline-2-ysulfamoyl}pyrazol-1 - polar I yl)-N,N-dimethylacetamide 5 o N NJ 0 N S-N N N - "1H H 0 0 10 HO "A28" 2-Dimethylaminomethyl-1-methyl-1H-imidazole-4- 1.72 / 586.68 sulfonic acid {3-[2-(3-hydroxybutoxy)-3,5- polar 1 dimethoxyphenylamino]quinoxalin-2-yl} amide 15 N N 0 N S 20 0 0

N-

HO "A29" 1-Difluoromethyl-1H-pyrazole-4-sulfonic acid {3-[2- 2.37 / 551.54 (3-hydroxypropoxy)-3,5-dimethoxyphenylamino]~ polar 1 25 quinoxalin-2-yl} amide H N N 0 FF %' S-N N 0 30 o o HO 35 WO 2012/052102 PCT/EP2011/004746 -78 "A30"I N-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxy- 2.50 / 511.56 phenylamino]quinoxalin-2-yl}benzenesulfonamide polar I 0 5 N NY o, 0 n NH SO OH 10 "A31" 2-Dimethylaminomethyl-1-methyl-1H-imidazole-4- 1.77 / 528.60 sulfonic acid [3-(2,3,5-trimethoxyphenylamino)- polar 1 quinoxalin-2-y] amide 15 \ N N 0 NO -O 0 20 "A32" 1-Methyl-1 H-imidazole-4-sulfonic acid {3-[2-(3- 2.27/ 529.58 hydroxy-2-methylpropoxy)-3,5-dimethoxy- polar 1 phenylaminolquinoxalin-2-yl} amide 25 0N N 0

OOO

N \ S-N N 1 5H H 0 0 30 OH 35 WO 2012/052102 PCT/EP2011/004746 -79 "A33 1 2-Dimethylaminomethyl-1-methyl-iH-imidazole-4- 1.70 / 572.65 sulfonic acid {3-[2-(3-hydroxypropoxy)-3,5- polar 1 dimethoxyphenylaminolquinoxain-2-yi} amide 5 N N 0 -S-N N 18K H N 00 0 10 HO 'A34" Ethyl (4-{3-[2-(3-hydroxypropoxy)-3,5-dimethoxy- 2.43 / 598.64 phenylamino]quinoxalin-2-ysulfamoyl}phenyl)- polar 1 carbamate 15 N N 0 0o 0 H J NH H 0 20 HO "rA35"r 1,1 -Dioxotetrahydro-1 -lambda*6*-thiophene-3- 2.19 / 553.62 sulfonic acid {3-[2-(3-hydroxypropoxy)-3,5- polar 1 dimethoxyphenylamino]quinoxalin-2-yl} amide 25 N 0 N X N N 0 0 H4 I II-NH 0 30 0 OH 35 WO 2012/052102 PCT/EP2011/004746 - 80 "A36" 3-Methanesulfonylpropan-1-sulfonic acid {3-[2-(3- 2.10 / 555.64 hydroxypropoxy)-3,5-dimethoxyphenylamino]- polar quinoxalin-2-yl} amide HO O=, S 2INH 10 S:rO OH "A39" C,C,C-Trifluoro-N-{3-[2-(3-hydroxypropoxy)-3,5- 2.43/ 503.46 dimethoxyphenylamino]quinoxalin-2-y}- polar 1 methanesulfonamide 15 N O N q, 20 F O OH "A40" CC,C-Trifluoro-N-[3-(2,3,5-trimethoxy- 2.65 / 459.41 phenylamino)quinoxalin-2-yl]methanesulfonamide polar 1 25 N N 0 F 11 F S--N N F O O 0 30 35 WO 2012/052102 PCT/EP2011/004746 -81 "A41" 5-Cyanothiophene-2-sulfonic acid {3-[2-(2- 2.61 / 590.67 methanesulfonylethoxy)-3,5-dimethoxy- polar I phenylamino]quinoxalin-2-yl} amide 5 N NN N N 0 o H NH 0 S S 10 N O "A42" 1-Methyl-1 H-imidazole-4-sulfonic acid {3-[2-(3- 2.22! 529.58 hydroxybutoxy)-3,5-dimethoxyphenylamino]- polar I quinoxalin-2-yl} amide 15 0 N N O 20 N OH "A43" 1-Methyl-I H-pyrazole-4-sulfonic acid {3-[2-(3- 2.26! 529.58 hydroxybutoxy)-3,5-dimethoxyphenylamino]- polar 1 quinoxalin-2-yl} amide 25 T NH O 30 N N OH 'H NMR (500 MHz, DMSO-d 6 + TFA-d1): 6 [ppm] 8.47 (s, 1H), 8.26 (d, J= 2.8, 1 H), 8.04 - 7.95 (m, 2H), 7.65 (dd, J = 7.7, 1.6, 1 H), 7.40 (pd, J = 7.2, 35 1.6, 2H), 6.41 (d, J= 2.8, 1 H), 4.00 (t, J = 7.1, 2H), 3.90 (s, 3H), 3.86 - 3.77 (m, 7H), 1.76 (q, J= 6.9, 2H), 1.10 (d, J = 6.2, 3H) WO 2012/052102 PCT/EP2011/004746 - 82 " t A44" 1-Methyl-1 H-pyrazole-4-sulfonic acid {3-[2-(3- 2.19 / 515.56 hydroxypropoxy)-3,5-dimethoxyphenylamino]- polar 1 quinoxalin-2-y} amide 5 N N 0 N 1 HH H \ 0 0 0 10 HO "A45" 4-Cyano-N-{3-[2-(3-hydroxybutoxy)-3,5-dimethoxy- 2.47 / 550.60 phenylamino]quinoxalin-2-yl}benzenesurfonamide polar 1 15 N N N 0 N O NH O OH 20 N "A46" 2-Cyano-N-{3-[2-(3-hydroxypropoxy)-3,5- 2.56 / 536.57 dimethoxyphenylamino]quinoxalin-2-y}- polar 1 benzenesulfonam ide 25 O0 N O H O 30 A N OH 35 WO 2012/052102 PCT/EP2011/004746 - 83 "A47" 1-Methyl-1 H-imidazole-4-sulfonic acid (3-{3,5- 2.26 / 559.61 dimethoxy-2-[2-(2-methoxyethoxy)ethoxy]- polar 1 phenylamino}quinoxalin-2-y) amide 5 0 N N O T H NNO0 0 NH H 0 0 0 10 \N "A48" 4-Cyano-N-(3-{3,5-dimethoxy-2-[2-(2-methoxy- 2.56 / 580.63 ethoxy)ethoxy]phenylamino}quinoxalin-2-yl)- polar 1 benzenesulfonamide 0 15 H 0 0 NH 20 N 7 N "A49" C, C,C-Trifluoro-N-(3-{2-[2-(2-hydroxyethoxy)- 2.40 / 533.49 ethoxy]-3,5-dimethoxyphenylamino)quinoxalin-2- polar 1 25 yl)methanesulfonamide I 0 N 0

H

30 N OS F F 35 WO 2012/052102 PCT/EP2011/004746 - 84 "A50" N-(4-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxy- 2.23 / 568.62 phenylamino]quinoxalin-2-ylsulfamoyl}phenyl)- polar 1 acetamide N HN NH H O /O N\ 0 10 HO "A51 5-Cyanothiophene-2-sulfonic acid {3-[2-(3- 2.44 / 542.60 hydroxypropoxy)-3,5-dimethoxyphenylamino]- polar 1 quinoxalin-2-yl} amide 15 N N-. N 0 0,NH O 20 S N-: 0 OH "A52" 1-Methyl-1H-imidazole-4-sulfonic acid {3-[2-(2- 2.06 / 547.62 methanesulfinylethoxy)-3,5-dimethoxy- polar 1 25 phenylamino]quinoxalin-2-yl} amide 0 H H?1 N N-S N O ON" N O 30 O=S 35 WO 2012/052102 PCT/EP2011/004746 - 85 "A53" 4-Fluoro-N-(3-{2-[2-(2-hydroxyethoxy)ethoxy]-3,5- 2.41 1 559.58 dimethoxyphenylamino}quinoxalin-2-yl)- polar 1 benzenesulfonamide 0-.

5 0 a OH N NH NH 0F 10 "A54" 1-Methyl-1H-imidazole-4-sulfonic acid {3-[3,5- 1.7 1 570.63 dimethoxy-2-(2-m orpholin-4-ylethoxy)- polar 1 phenylamino]quinoxalin-2-yl} amide 0 15 O NHH OS N N N N 20 a "A55" 1-Methyl-1 H-imidazole-4-sulfonic acid {3-[2-(2- 2.21 / 563.62 methanesulfonylethoxy)-3,5-dimethoxy- polar 1 phenylamino]quinoxalin-2-yl} amide 25 a N N OON N / 1 N 300 35 WO 2012/052102 PCT/EP2011/004746 - 86 "A56" Propane-i1-sulfonic acid (3-{2-[2-(2-hydroxy- 2.30 / 507.57 ethoxy)ethoxy]-3,5-dimethoxyphenylamino}- polar 1 quinoxalin-2-yl) amide 5 0 0 s N NH N N, 10 "A58" N-(3-{2-[2-(2-Hydroxyethoxy)ethoxy]-3,5- 2.38 / 541.59 dimethoxyphenylamino}quinoxalin-2-yl)- polar 1 benzenesufonamide 15 N N N OH 9 AIH H 0 fOH 200 "A59" 5-Cyanothiophene-2-sulfonic acid (3-{2-[2-(2- 2.38 / 572.63 hydroxyethoxy)ethoxy]-3,5-dimethoxy- polar 1 phenylamino}quinoxalin-2-y) amide 25 N X N O H N 0 305 35 WO 2012/052102 PCT/EP2011/004746 -87 "A60" Thiophene-2-sulfonic acid [3-(2-{2-[(2-hydroxy- 1.80 / 560.66 ethyl) methylam i no]ethoxy}-3,5-dimethoxy- polar 1 phenylamino)quinoxalin-2-y] amide 5 N N 0 0 10 HO N "A61" N-(3-{2-[2-(2-Hydroxyethoxy)ethoxy]-3,5- 2.41 1 571.62 dimethoxyphenylamino}quinoxalin-2-yl)-4- polar 1 methoxybenzenesulfonamide 15 --o N N-S 0 ON N 20 HO O H NMR (500 MHz, DMSO-d 6 + TFA-d1): 5 [ppm] 8.23 (d, J = 2.8 Hz, 1H), 8.06 - 8.01 (m, 2H), 8.00 - 7.96 (m, IH), 7.63 (dd, J = 1.8, 7.6 Hz, 1H), 7.43 - 7.35 (m, 2H), 7.14 (d, J = 8.9 Hz, 2H), 6.39 (d, J = 2.7 Hz, 1H), 4.02 25 (t, J = 5.0 Hz, 2H), 3.86 (s, 3H), 3.83 (s, 3H), 3.82 (s, 3H), 3.53 (t, J = 5.0 Hz, 2H), 3.43 (t, J = 5.1 Hz, 2H), 3.37 (t, J = 5.1 Hz, 2H) "A62" N-[4-(3-{2-[2-(2-Hydroxyethoxy)ethoxy]-3,5- 2.18 / 598.64 dimethoxyphenylamino}quinoxalin-2-ylsulfamoyl)- polar 1 phenylacetamide 30 0 \ / $, NOH NN N OSN 350- WO 2012/052102 PCT/EP2011/004746 -88 "H NMR (500 MHz, DMSO-d 6 + TFA-d1): 6 [ppm] 8.24 (d, J = 2.8, 1H), 8.05 - 8.00 (m, 2H), 7.98 (dd, J = 1.7, 7.7, 1H), 7.83 (d, J = 8.8, 2H), 7.64 (dd, J = 1.7, 7.7, 1 H), 7.43 - 7.35 (m, 2H), 6.40 (d, J = 2.8, 1 H), 4.02 (t, 2H), 5 3.84 (s, 3H), 3.83 (s, 3H), 3.51 (t, J = 5.0, 2H), 3.44 (t, J = 5.2, 2H), 3.36 (t, J = 5.2, 2H), 3.37 (s, 3H) "A63" 3 -Cyano-N-(3-{2-[2-(2-hydroxyethoxy)ethoxy]-3,5- 2.36 / 566.60 dimethoxyphenylaminoquinoxalin-2-y)- polar 1 benzenesulfonamide 10 0 OH / \ O 0 N N O 0 01 15 0 N H NMR (500 MHz, DMSO-de + TFA-d1): 6 [ppm] 8.59 (t, J = 1.5, 1H), 8.44 -8.39 (m, 1H), 8.27 (d, J = 2.8, 1H), 8.13 - 8.08 (m, 1H), 7.99 (dd, J 20 = 1.5, 7.9, 1 H), 7.84 (t, J = 7.9, 1H), 7.68 (dd, J = 1.5, 7.8, 1 H), 7.47 7.37 (m, 2H), 6.41 (d, J = 2.7, 1 H), 4.07 (t, J = 4.8, 2H), 3.84 (s, 6H), 3.52 (t, J = 4.8, 2H), 3.45 (t, J = 5.2, 2H), 3.38 (t, J = 5.2, 2H) "A64" Thiophene-2-sulfonic acid (3-{2-[2-(2-hydroxy- 2.35 / 547.62 ethoxy)ethoxy]-3,5-dimethoxyphenylamino}- polar 1 25 quinoxalin-2-yl) amide \/ $ OH N NO 0 30 -- H 0 35 WO 2012/052102 PCT/EP2011/004746 -89 'H NMR (500 MHz, DMSO-d 6 + TFA-d1): 6 [ppm] 8.25 (d, J = 2.8 Hz, 1H), 8.04 (dd, J = 1.4, 7.9 Hz, 1 H), 7.97 - 7.92 (m, 2H), 7.66 (dd, J = 1.4, 7.9 Hz, I H), 7.46 - 7.37 (m, 2H), 7.19 (dd, J = 3.9, 4.8 Hz, 1 H), 6.41 (d, J 5 = 2.7 Hz, 1H), 4.08 (t, J = 5.0 Hz, 2H), 3.85 (s, 3H), 3.84 (s, 3H), 3.64 (t, J = 5.0 Hz, 2H), 3.48 - 3.41 (m, 4H) "A65" Pyridine-3-sulfonic acid (3-{2-[2-(2-hydroxy- 2.17 / 542.58 ethoxy)ethoxy]-3,5-dimethoxyphenylamino)- polar 1 quinoxalin-2-yI) amide 10 10 OH S-N N 0 15 0 1 H NMR (500 MHz, DMSO-d 6 + TFA-d1): & [ppm] 9.41 (d, J = 1.7 Hz, 1H), 8.97 (dd, J = 1.4, 5.2 Hz, 1 H), 8.79 - 8.73 (m, 1 H), 8.22 (d, J = 2.8 Hz, 1H), 7.99 (dd, J = 1.4, 7.9 Hz, 1H), 7.92 (dd, J = 5.3, 8.1 Hz, IH), 7.67 20 (dd, J = 1.4, 7.9 Hz, 1H), 7.43 (dtd, J = 1.5, 7.3, 16.8 Hz, 2H), 6.41 (d, J = 2.8 Hz, 1H), 4.04 (t, J = 4.8 Hz, 2H), 3.83 (s, 3H), 3.82 (s, 3H), 3.52 (t, J = 4.8 Hz, 2H), 3.43 (t, J = 5.3 Hz, 2H), 3.37 (t, J = 5.0 Hz, 2H) "A66" Thiophene-2-sulfonic acid {3-[2-(2-hydroxyethoxy)- 2.39 / 503.56 3,5-dimethoxyphenylamino]quinoxalin-2-y} amide polar 1 25 OH 09 N \/N O 0 S-N N u H H 30 0 0 'H NMR (500 MHz, DMSO-de + TFA-d 1 ): 6 [ppm] 8.24 (d, J = 2.8 Hz, 1H), 8.03 (dd, J = 1.6, 7.8 Hz, IH), 7.96 (dd, J = 1.3, 3.7 Hz, 1H), 7.92 (d, J = 4.9 Hz, IH), 7.66 (dd, J = 1.5, 7.8 Hz, 1H), 7.45 - 7.36 (m, 2H), 7.19 35 (dd, J = 3.8, 4.9 Hz, IH), 6.42 (d, J = 2.7 Hz, 1H), 3.98 (t, J = 5.6 Hz, 2H), 3.85 (s, 3H), 3.84 (s, 3H), 3.66 (t, J = 5.6 Hz, 2H) WO 2012/052102 PCT/EP2011/004746 - 90 "A67" Pyridine-3-sulfonic acid (3-{2-[2-(2-hydroxy- 2.12 / 590.64 ethansulfonyl)ethoxy]-3,5-dimethoxyphenylamino}- polar 1 quinoxalin-2-yI) amide HO 5 0 N 0 N N O O 10 0_ H NMR (500 MHz, DMSO-d 6 + TFA-d1): 5 [ppm] 9.47 (d, J= 2.0 Hz, 1H), 9.00 (dd, J = 1.3, 5.2 Hz, 1 H), 8.89 - 8.81 (m, I H), 8.12 (d, J = 2.7 Hz, 1 H), 8.02 (dd, J = 1.4, 7.9 Hz, IH), 7.97 (dd, J= 5.3, 8.1 Hz, 1H), 7.69 (dd, 15 J = 1.4, 7.8 Hz, I H), 7.51 - 7.38 (m, 2H), 6.46 (d, J = 2.7 Hz, 1 H), 4.29 (t, J = 6.4 Hz, 2H), 3.87 (s, 3H), 3.87 - 3.81 (m, 5H), 3.50 (t, J = 6.4 Hz, 2H), 3.33 (t, J= 5.9 Hz, 2H) "A68" Pyridine-3-sulfonic acid [3-(2-{2-[(2-hydroxyethyl)- 1.69 / 555.62 20 methylaminolethoxy}-3,5-dimethoxyphenylamino)- polar 1 quinoxalin-2-y] amide PN 0- N 25 N 0 N 5 H o - 0 0 / HO N 30 35 WO 2012/052102 PCT/EP2011/004746 - 91 "A69" 4-(3-{2-[2-(2-Hydroxyethoxy)ethoxy]-3,5- 2.18 / 612.67 dimethoxyphenylamino}quinoxalin-2-ylsulfamoyl)- polar 1 N,N-dimethylbenzamide -0\ 5 $ OH ON >N 0 0 0 ~S-N N0 -N - 0 10 H NMR (500 MHz, DMSO-de + TFA-d 1 ): 6 [ppm] 8.26 (d, J = 2.8 Hz, 1H), 8.17 (d, J= 8.4 Hz, 2H), 8.00 (dd, J= 1.5, 7.9 Hz, 1H), 7.71 - 7.61 (m, 3H), 7.47 - 7.37 (m, 2H), 6.41 (d, J = 2.8 Hz, 1 H), 4.05 (t, J = 4.9 Hz, 2H), 3.84 (s, 6H), 3.53 (t, J= 4.9 Hz, 2H), 3.43 (t, J = 5.1 Hz, 2H), 3.37 (t, J= 5.1 Hz, 15 2H), 3.04 (s, 3H), 2.93 (s, 3H) "A70" 4-Cyano-N-{3-[3,5-dimethoxy-2-(2-morpholin-4-yl- 1.88 / 591.65 ethoxy)phenylamino]quinoxain-2-yl- polar 1 benzenesulfonamide 0 20 N 4N O O -1 N0 N- S-N N 0 25 0_ 'H NMR (500 MHz, DMSO-d 6 + TFA-d1): 6 [ppm] 8.33 - 8.27 (m, 2H), 8.14 (d, J = 2.8 Hz, 1H), 8.13 - 8.07 (m, 2H), 8.04 (dd, J = 1.5, 8.0 Hz, 1H), 7.68 (dd, J= 1.4, 7.9 Hz, 1H), 7.44 (dtd, J= 1.5, 7.3, 15.1 Hz, 2H), 6.47 (d, 30 J = 2.8 Hz, 1H), 4.19 (t, J = 4.94 Hz, 2H), 4.06 (d, J = 11.8 Hz, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 3.80 (t, J= 11.8 Hz, 2H), 3.56 (d, J= 12.3 Hz, 2H), 3.44 (t, J = 5.0 Hz, 2H), 3.25 (td, J = 3.5, 12.5 Hz, 2H) 35 WO 2012/052102 PCT/EP2011/004746 - 92 "A71" 3,4-Difluoro-N-{3-{2-(3-hydroxypropoxy)-3,5- 2.55 / 547.54 dimethoxyphenylamino]quinoxalin-2-yl}- polar I benzenesulfonamide 5 F SN N0 FQ 0p "H H 0 0 F HO, O O 10 "A72" 4 -Cyano-N-(3-{2-[2-(2-hydroxyethanesulfinyl)- 2.19 / 598.67 ethoxyl-3,5-dimethoxyphenylamino}quinoxalin-2- polar I yl)benzenesulfonamide 0 15 NH

N

20 0N OH I-N 'H NMR (500 MHz, DMSO-d 6 + TFA-d1): 6 [ppm] 8.27 (d, J= 8.5 Hz, 2H), 8.18 (d, J= 2.8 Hz, 1H), 8.08 (dd, J= 1.3, 8.4 Hz, 2H), 8.00 (dd, J = 1.2, 7.9 Hz, 1H), 7.67 (d, J = 7.7 Hz, 1H), 7.48 - 7.37 (m, 2H), 6.42 (d, J = 2.5 Hz, 25 1 H), 4.28 (ddd, J = 5.5, 8.0, 10.7 Hz, 1H), 4.18 (dt, J = 5.6, 11.0 Hz, 1H), 3.84 (s, 3H), 3.83 (s, 3H), 3.79 (dt, J = 5.9, 12.3 Hz, 2H), 3.12 - 3.02 (m, 1H), 2.95 (ddd, J = 4.3, 7.8, 14.1 Hz, 2H), 2.83 (dt, J = 4.5, 13.2 Hz, 1H) 30 35 WO 2012/052102 PCT/EP2011/004746 - 93 "A73" 3,4-Difluoro-N-(3-{2-[2-(2-hyd roxyethoxy)ethoxy]- 2.49 / 577.57 3,5-dimethoxyphenylamino}quinoxalin-2-yl)- polar 1 benzenesulfonamide 5 N -4N O F /\ -N tN 0 HH |F ,.,o

O

10 HO "A74" 4-Cyano-N-{3-[2-(2,3-dihydroxypropoxy)-3,5- 2.26 / 552.57 dimethoxyphenylamino]quinoxalin-2-yl}- polar 1 benzenesulfonamide HO 15 O N\/N 0 0 N-=-- S-N/ N N - " H H 20 H NMR (500 MHz, DMSO-d 6 + TFA-d1): 5 [ppm] 8.31 (d, J 8.5 Hz, 2H), 8.21 (d, J = 2.8 Hz, 1 H), 8.07 (d, J = 8.6 Hz, 2H), 7.99 (dd, J = 1.4, 7.9 Hz, I H), 7.65 (dd, J = 1.4, 7.8 Hz, 1 H), 7.46 - 7.37 (m, 2H), 6.41 (d, J = 2.8 Hz, I H), 3.96 (dd, J = 4.5, 10.3 Hz, 1 H), 3.85 - 381 (m, 7H), 3.66 - 3.60 (m, 25 1H), 3.41 - 3.33 (m, 2H) "A75" 1-Methyl-1 H-imidazole-4-sulfonic acid {3-[2-(2,3- | 2.00 / 531.55 dihydroxypropoxy)-3,5-dimethoxyphenylamino]- polar 1 quinoxalin-2-yl} amide HO 30 ) OH N N O O 35N &S-N N0 N 11 350 WO 2012/052102 PCT/EP2011/004746 - 94 'H NMR (500 MHz, DMSO-d 6 + TFA-d1): 5 [ppm] 8.62 (s, 1H), 8.22 (d, J = 1.7 Hz, 2H), 7.92 (dd, J = 1.5, 7.9 Hz, I H), 7.69 (dd, J = 1.5, 7.9 Hz, 1 H), 7.49 - 7.39 (m, 2H), 6.44 (d, J = 2.9 Hz, 1 H), 4.03 (dd, J = 4.4, 10.3 5 Hz, 1 H), 3.89 - 3.85 (m, 4H), 3.85 (s, 3H), 3.84 (s, 3H), 3.75 (td, J= 5.3, 10.0 Hz, 1H), 3.47 (qd, J = 5.3, 11.2 Hz, 2H) "A76" 4-Cyano-N-(3-{2-[2-(2-hydroxyethanesulfonyl)- 2.33 / 614.66 ethoxy]-3,5-dimethoxyphenylamino}quinoxalin-2- polar 1 yl)benzenesulfonamide 10 HO 0 \ _ N K t 15 N=A N0 0 0 H NMR (500 MHz, DMSO-d 8 + TFA-d1): 6 [ppm] 8.34 - 8.27 (m, 2H), 8.17 (d, J = 2.8 Hz, 1H), 8.11 - 8.05 (m, 2H), 8.03 (dd, J = 1.6, 7.9 Hz, 1H), 7.68 20 (dd, J= 1.5, 7.8 Hz, 1H), 7.48 - 7.38 (m, 2H), 6.44 (d, J= 2.8 Hz, 1H), 4.27 (t, J = 6.5 Hz, 2H), 3.87 (s, 3H), 3.86 - 3.82 (m, 5H), 3.44 (t, J = 6.5 Hz, 2H), 3.32 (t, J = 5.9 Hz, 2H) "A77" 1-Methyl-1H-imidazole-4-sulfonic acid (3-{2-[2-(2- 2.09 / 593.65 25 hydroxyethanesulfonyl)ethoxy]-3,5-dimethoxy- polar 1 phenylamino}quinoxalin-2-yl) amide HO 0 30 N KY N NO NN 0 35 WO 2012/052102 PCT/EP20111/004746 -.95 1 H NMR (500 MHz, DMSO-d 6 + TFA-d1): 5 [ppm] 8.54 (d, J= 0.7 Hz, 1H), 8.21 (d, J= 1.3 Hz, 1H), 8.18 (d, J= 2.8 Hz, 1H), 7.93 (dd, J= 1.6, 7.8 Hz, 1H), 7.71 (dd, J= 1.6, 7.8 Hz, 1H), 7.45 (pd, J= 1.6, 7.3 Hz, 2H), 6.45 (d, 5 J= 2.8 Hz, 1 H), 4.31 (t, J = 6.5 Hz, 2H), 3.89 - 3.86 (n, 5H), 3.85 (s, 3H), 3.84 (s, 3H), 3.57 (t, J = 6.6 Hz, 2H), 3.37 (t, J= 6.0 Hz, 2H) "A78" 4-Cyano-N-[3-(2-{2-[(2-hydroxyethyl)methylam ino] 1.84 / 579.64 ethoxy}-3,5-dimethoxyphenylamino)quinoxalin-2- polar 1 yl]benzenesulfonamide 10 N H 0 'N 15 N INN OH formate 20 "A79" Pyridine-3-sulfonic acid {3-[2-(3-hydroxypropoxy)- 2.22 / 512.55 3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide polar 1 '-1 N 1j' N4 0 25 N O N N H 0 O H 30 35 WO 2012/052102 PCT/EP2011/004746 -96 "A80" 4-Cyano-N-(3-{2-[2-(2-hydroxyethoxy)ethoxy]-3,5- 2.37 / 566.60 dimethoxyphenylamino}quinoxalin-2-yl)- polar 1 benzenesulfonamide 5 N N 0 N- / -N N - H H 0 0 0 HO O O-~ / 10 'H NMR (500 MHz, DMSO-d 6 + TFA-d1): 6 [ppm] 8.33 - 8.26 (m, 2H), 8.25 (d, J = 2.8 Hz, 1H), 8.16 - 8.07 (m, 2H), 8.01 (dd, J = 1.6, 7.9 Hz, 1H), 7.67 (dd, J = 1.6, 7.8 Hz, 1 H), 7.43 (pd, J= 1.6, 7.3 Hz, 2H), 6.41 (d, J= 2.8 Hz, 1 H), 4.07 - 3.97 (t, J = 4.8 Hz, 2H), 3.83 (s, 6H), 3.52 - 3.45 (m, 2H), 3.43 15 (t, J= 5.1 Hz, 2H), 3.35 (t, J= 5.3 Hz, 2H) "A81" 1-Methyl-IH-imidazole-4-sulfonic acid (3-{2-[2-(2- 2.09 / 545.58 hydroxyethoxy)ethoxy]-3,5-dimethoxy- polar 1 phenylamino}quinoxalin-2-yl) amide 20 0NN N 0 S- N N-- N 5 H 0 0 25 HO 0 /o 'H NMR (500 MHz, DMSO-de + TFA-d 1 ): 6 [ppm] 8.52 (s, 1H), 8.22 (d, J = 2.8 Hz, 1 H), 8.20 (d, J = 1.3 Hz, 1 H), 7.91 - 7.87 (m, 1 H), 7.71 - 7.68 (m, 1H), 7.48 - 7.40 (m, 2H), 6.42 (d, J = 2.9 Hz, 1H), 4.08 (t, 2H), 3.85 (s, 30 3H), 3.84 (s, 3H), 3.83 (s, 3H), 3.66 (t, J= 4.9 Hz, 2H), 3.49 - 3.39 (m, 4H) 35 WO 2012/052102 PCT/EP2011/004746 - 97 "A82" 4-Cyano-N-{3-[2-(3-hydroxypropoxy)-3,5- 2.42 / 536.57 dimethoxyphenylamino]quinoxalin-2-yl} polar 1 benzenesulfonamide 5 N N 0 0 N=~- N 0 0 10 HO O /O 'H NMR (500 MHz, DMSO-d 6 + TFA-d1): 5 [ppm] 8.25 (m, 3H), 8.09 (d, J = 8.6 Hz, 2H), 8.01 (dd, J = 1.5, 7.9 Hz, 1 H), 7.67 (dd, J= 1.4, 7.9 Hz, I H), 7.50 - 7.36 (m, 2H), 6.40 (d, J = 2.8 Hz, 1 H), 3.90 (t, J = 7.0 Hz, 2H), 3.82 (d, J= 3.1 Hz, 6H), 3.40 (t, J= 6.2 Hz, 2H), 1.59 (p, J= 6.6, 2H) "A83" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(5- 2.39 / 507.5 difluoromethoxy-2,3~dimethoxyphenylamino)- polar 1 quinoxalin-2-yl] amide 20 SN

O

N N S-N N .

O H 0 F-'' 25 F "A84" 4-Cyano-N-[3-(5-difluoromethoxy-2,3-dimethoxy- 2.76 / 528.5 phenylamino)quinoxalin-2-yl]benzenesulfonamide polar 1 Q/ 30 N N 0 0 N -N NH 0 0 F H F 35 WO 2012/052102 PCT/EP20111004746 - 98 "A85" 4 -[3-(5-Difluoromethoxy-2,3-dimethoxy- 2.54 / 574.6 phenylamino)quinoxa!in-2-ylsulfamoyl]-N,N- polar 1 dimethylbenzamide F 0 F 0 O NH Ose N 10 N A86" 1-Methyl-1H-imidazole-4-sulfonic acid {3-[2-(3- 2.23 / 515.56 hydroxypropoxy)-3,5-dimethoxyphenylamino]- polar 1 quinoxalin-2-yl} amide 15 HO O N X N 0 20 H H 0 "A87" 4

-{

3 -[2-(3-Hydroxypropoxy)-3,5-dimethoxy- 2.31 / 582.6 phenylamino]quinoxalin-2-ylsulfamoyl}-N,N- polar 1 25 dimethylbenzamide 0- OH O\/O NH 03 35 WO 2012/052102 PCT/EP2011/004746 - 99 "A88" 4-{3-[2-(2-Hydroxyethoxy)-3,5-dimethoxy- 2.29 / 501.53 phenylaminoquinoxalin-2-ylsulfamoy}-N,N- polar 1 dimethylbenzamide 0- OH 5 o 0 NH 0 0 ' H // 10 "A89" 1-Methyl-1 H-imidazole-4-sulfonic acid {3-[2-(2- 2.18/ 501.53 hydroxyethoxy)-3,5-dimethoxyphenylamino]- polar 1 quinoxalin-2-yl} amide 0 00 15 H H 1 N - N-S- N 151 O O N N HO 20 "A90"T NN-Dimethyl-4-[3-(2,3,5-trimethoxyphenyiamino)- 2.33 / 538.6 quinoxalin-2-ylsulfamoyl]benzamide polar 2 \/ 0 H HP N N 25 00NY "A9 1" 4 -Cyano-N-[3-(2,3,5-trimethoxyphenylamino) 2.62 / 492. 52 30 quinoxalin-2-y]benzenesulfonamide polar 1 -o 0 /\H H // N N-S N -O 0 N N 35 WO 2012/052102 PCTIEP2011/004746 - 100 "A92" 1-Methyl-i H-imidazole-4-sulfonic acid [3-(2,3,5- 2.26 / 471.50 trimethoxyphenylamino)quinoxalin-2-ylJ amide polar 1 -o H H 0 N N-S -O O N N "A93" N-(2,2-Difluoroethyl)-4-{3-[2-(3-hydroxypropoxy)- 2.37 / 618.6 10 3 ,5-dimethoxyphenylaminolquinoxalin-2- polar ylsulfamoyl}benzamide 0~ N A 15 N N 0 F 0 H I F- 0 F OH OO 0 20 "A94" 2-Dimethylaminomethyl-1-methyl-iH-imidazole-4- 1.71 / 570.7 sulfonic acid {3-{2-(4-hydroxybutyl)-3,5-dimethoxy- polar phenylamino]quinoxalin-2-yl} amide OH 25 -0 - NH N N O N N 30 35 WO 2012/052102 PCT/EP2011/004746 - 101 "A95" 4-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxy- 2.46 / 636.6 phenylamino]quinoxalin-2-ylsulfamoyl}-N-(2,2,2- polar trifluoroethyl)benzamide 5 N FN N 0J 5 F ': N O F INH H 10 FHN 'O 1 OH "A96" 2-Cyanoethanesufonic acid {3-[2-(3-hydroxy- 2.21 / 488.5 propoxy)-3,5-dimethoxyphenylamino]quinoxarin-2- polar yl} amide 15 0 "N O N 0 H NH 0 20 N O OH "A97" 3

-{

3

-[

2 -(3-Hydroxypropoxy)-3,5-dimethoxy- 2.26 / 582.6 phenylamino]quinoxalin-2-ylsulfamoyl}-N,N- polar dimethylbenzamide 25Q / N\/N 0 S-N N 1- "H H 30 0 0 0

N

HO 35 WO 2012/052102 PCT/EP2011/004746 -102.

"A98" 4-(3,3-Difluoroazetidine-1 -carbonyl)-N-{3-[2-(3- 2.41/ 630.6 hydroxypropoxy)-3,5-dimethoxyphenylamino]- polar quinoxalin-2-yl}benzenesulfonamide 5F N O F 'NH H 10 N O OH "A99" N-{3-[2-(3-Hydroxybutoxy)-3,5-dimethoxy- 2.271 / 63.5 phenylamino]quinoxalin-2-yl}methanesulfonamide polar 1 15 q 0 -N N O\NH OH 3=0 20 / "Al 00" 1-Methyl-1 H-pyrazole-3-sulfonic acid {3-[2-(3- 2.33/ 529.6 hydroxybutoxy)-3,5-dimethoxyphenylamino]- polar quinoxalin-2-yl} amide 0 NN N0 30 OH 35 WO 2012/052102 PCT/EP2011/004746 - 103 "A10111 Thiazole-5-sulfonic acid {3-[2-(3-hydroxybutoxy)- 2.25 / 532.6 3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide polar 0~~ 5 N O N'-. NJ 0 0 H N 0 tSO OH 10 "Al 02" 4-(Azetidine-1-carbonyl)-N-{3-[2-(3-hydroxy- 2.27 / 594.7 propoxy)-3,5-dimethoxyphenylamino]quinoxalin-2- polar yil}benzenesulfonamide N 0 15 N O N N O 0 H O OH 20 0 "Al 03" 1-Difluoromethyl-lH-pyrazole-4-sulfonic acid {3-[2- 2.45 / 565.6 (3-hydroxybutoxy)-3,5-dimethoxyphenylam ino]- polar quinoxalin-2-yi} amide 25 N N -NH Oj, 30 N 35 WO 2012/052102 PCTIEP2011/004746 -104 "A104" 2.35 / 478.5 0 O polar 0 N NH 5 N N 10 "A105" 3 -{3-[ 2 -(3-Hydroxypropoxy)-3,5-dimethoxy- 2.46 / 636.6 phenylamino]quinoxaiin-2-ylsulfamoyl}-N-(2,2,2- polar trifluoroethyl)benzamide 15 0 N .' N "N N NH O H F F HO F H0 'N O > 20 "Al 07" 3-(3,3-Difluoroazetidine-1 -carbonyl)-N-{3-[2-(3- 2.10 / 630.6 hydroxypropoxy)-3,5-dimethoxyphenylamino]- polar quinoxalin-2-yl}benzenesulfonamide 25 N 3 0 FO 300 HO F 35 WO 2012/052102 PCT/EP2011/004746 - 105 "A108" 3-(Azetidine-1 -carbony)-N-{3-[2-(3-hydroxy- 2.27 / 594.7 propoxy)-3,5-dimethoxyphenylamino]quinoxalin-2- polar yl}benzenesulfonamide 5 N N 0 S-N N 0 O 0 0 10 N HO "Al 12" 1-Methyl-IH-pyrazole-3-sulfonic acid (3-{2-[2-(2- 2.18 / 545.6 hydroxyethoxy)ethoxy-3,5-dimethoxy- polar phenylamino}quinoxalin-2-yl) amide 15 N N 0 20 0 0 0 HO "Al 13" 2 -Dimethylaminomethyl-1-methyl-1H-imidazole-4- 1.73 / 586.7 25 sulfonic acid {3-[2-(4-hydroxybutoxy)-3,5- polar dimethoxyphenylaminojquinoxalin-2-yi} amide N N 1 30 N N \kNH H 0 0 N

N

35 OH 35 WO 2012/052102 PCT/EP2011/004746 -106 "Al 14" C,C-Difluoro-N-(3-[2-(3-hydroxypropoxy)-3,5- 2.35 / 485.5 dimethoxyphenylamino]quinoxalin-2-y1}- polar methanesulfonamide 5 1 0 5 N N N 0 10 H I H \\ NH 0 FO 10 F O H "Al 15" C,C-Difiuoro-N-{3-[2-(3-hydroxybutoxy)-3,5- 2.43 / 499.5 dimethoxyphenylamino]quinoxalin-2-yl}- polar 15 methanesulfonamide N N 0 20 F S-N N F 0 0 0 HO "Al 17" 1-Methyl-1H-pyrazole-3-sulfonic acid {3-[2-(4- 2.28! 513.6 25 hydroxybutyl)-3,5-dimethoxyphenylamino]- polar quinoxalin-2-yl} amide N N 0 30 o N I I S -N Nl 0 0 HO 35 WO 2012/052102 PCT/EP2011/004746 -107 "Al 19" 2,2-DifIuoro-2-(3-{3-[2-(3-hydroxypropoxy)-3,5- 2.35 / 622.6 dimethoxyphenylamino]quinoxalin-2-ysulfamoyi}- polar pyrazol-1 -yl)-N, N-dimethylacetamide 5 IN F N N N O N NH H 100 10 N_ HO "A120" 2 -(3-{ 3

-[

2 -(3-Hydroxybutoxy)-3,5-dimethoxy- 2.21 / 600.7 15 phenylamino]quinoxalin-2-ylsulfamoyl}pyrazol- - polar yl)-N, N-dimethylacetamide IN' / N 20 0 HN N k.-NH H 0 O N 0 -0

N

HO 25 "A121" 1-Methyl-I H-pyrazole-3-sulfonic acid [3-(2,3,5- 2.41 / 471.5 trimethoxyphenylamino)quinoxalin-2-yl] amide polar N N 0 30 NN'N H -O 0 35 WO 2012/052102 PCT/EP2011/004746 -108 "A122" 2-(3-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxy- 2.14 / 586.6 phenylamino]quinoxalin-2-ylsulfamoyl}pyrazol-1 - polar yl)-N,N-dimethylacetamide 5 D N ( N 0 0 NH H 10N S S\\ N N O 10 N- OH "A123" 2-Diethylaminomethyl-1 -methyl-I H-imidazole-4- 1.76 / 614.7 sulfonic acid {3-[2-(3-hydroxybutoxy)-3,5- polar dimethoxyphenylaminolquinoxaiin-2-y} amide 15 'N 0 N 'K-NH H 20 N NJ HO "A124" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(2- 2.06 / 499.5 hydroxymethyl-7-methoxy-2,3-dihydrobenzo-1,4- polar 25 dioxin-5-ylamino)quinoxalin-2-yl] amide 0 N 0 0 H 30 NH 0 \-N 0 OH 35 WO 2012/052102 PCT/EP2011/004746 -109 "Al 25" 1-Methyl-IH-pyrazole-3-sulfonic acid {3-[2-(3- 2.37 1 543.6 hydroxy-3-methyl butoxy)-3,5-d imethoxy- polar phenylamino]quinoxalin-2-yl} amide 5 N N 0 SS-N N0 0 10

HO

"Al 26" 2-Diethylaminomethyl-I -methyl-I H-imidazole-4- 1.78 / 600.7 sulfonic acid {3-[2-(3-hydroxypropoxy)-3,5- polar dimethoxyphenylamino]quinoxalin-2-yl} amide 15 N- 011i4 N N N 0 20 0 H HO "A127" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(3- 2.14 / 499.5 25 hydroxymethyl-7-methoxy-2,3-dihydrobenzo-1,4- polar dioxin-5-ylamino)quinoxalin-2-y] amide 300 N 30 N ""N \\ -NH H0 HO 35 WO 2012/052102 PCT/EP2011/004746 - 110 "A1 28" 2-Dimethylaminomethyl-1 -methyl-1 H-imidazole-4- 1.76 / 600.7 sulfonic acid {3-12-(3-hydroxy-3-methylbutoxy)-3,5- polar dimethoxyphenylamino]quinoxalin-2-yl} aide 5 N N 0 N SN N II H H 0 0 10 N-. HO "A131" N,N-Dimethyl-2-{3-[3-(2,3,5-trimethoxy- 2.29 / 542.6 phenylamino)quinoxalin-2-ysufamoyl]pyrazol-1 - polar yl}acetamide 15 0N N 0 N1 "HN H 0 20 0 0 Examples of the preparation of amine building blocks: 25 Preparation of the aniline building block for "A6", "AT: 30 35 WO 2012/052102 PCT/EP2011/004746 - 111 rNI aeu u U separation of the reflux + Iregioisomers by o NH O NH silica-gel chromatography 05NH O NH 0 o O Sonogashira O coupling

H

2 /Pd/C N O 10 H o NH O NH OH OH 15 O KOH, ethylene glycol OH 00COH OT NH

NH

2 20 Preparation of the aniline building block for "A5": 0 0 H O O O 25 0 Br 0 0 OH tetrabutylammonium bromide O + K 2 C0 3 , -N, O' O reflux on a water separator ' 64% 0 1 30 N H 2 /Pd/C N LiBH 4 , methanol, diethyl ether, o 0 C 0 OH 0 OH

NH

2 0 '0 66% 62% 35 Preparation of the aniline building block for "Al 5" and "Al 6": WO 2012/052102 PCT/EP2011/004746 -112 0 0 1. KOH, heating 0 O 2. HCI OH CuO, quinoline 0 0 0 O -N + 0 H 200'C, 2h O'J O OJ 59% O '0 0 'N,0 59 5 0 SnC 2 , EA, ethanol O'N 0 70*C, 1h 100 -N'0 60% NH 2 42 10 N2 42% Preparation of the aniline building block for "A124" and "Al 27": O O OH 'Nq O - UH2/Pd/C H Pd/C OH + 0 o OH 0 '0 0 '0 -0 P i OChromatographic separation of the regioisomers }HJPJIC HP/ 25 U ' N o OH U ' N 250 0) ,OH NH 2 NH1 2 30 Example 4 Preparation of 4 -dimethylaminomethyvN-{3-[2-(3hydrxyprpoxy)-3,5-dimeth oxyphenylaminO]quinOxalin-2-yllbenzenesulfonamide ("A38") 35 WO 2012/052102 PCT/EP2011/004746 - 113 0 0~ o s a 0 N N ~NH N NH A f 4 LiA H 4 , TH Eao a N NH OH NH O 0=5=0 0== 10 0 NN A total of 4 equivalents of LiAIH 4 , dissolved in THF, are added to 200 mg of 4 -{3-[ 2 -(3-hydroxypropoxy)-3,5-dimethoxyphenylamino]quinoxalin-2-yl 15 sulfamoyl}-N,N-dimethylbenzamide, dissolved in about 10 ml of THF, at 0"C (ice bath) in a multinecked flask which has been dried by heating, and the mixture is stirred at RT until the starting material has reacted virtually completely (several hours, HPLC check). The reaction mixture is quenched 20 by addition of 5 ml of methanol. The solution is acidified until everything dissolves, evaporated somewhat and purified by preparative HPLC on silica gel RP18 (acetonitrile, water), giving 75 mg of 4-dimethylaminomethyl-N-{3-[2-(3-hydroxypropoxy)-3,5 25 dimethoxyphenylamino]quinoxalin-2-yl}benzenesulfonamide as yellow solid (yield 36%); MS-FAB (M+H*) = 568.2; Rf (polar method): 1.85 min. The following compounds are obtained analogously: 30 35 WO 2012/052102 PCT/EP2011/004746 -114 Compound Name and/or structure HPLC MS-FAB No. Rr [min] / [M+H]* method "A23" 1-(2-Dimethylamino-ethyl)-1 H-pyrazole-4-sulfonic 1.76 / 572.65 5 acid {3-[2-(3-hydroxypropoxy)-3,5-dimethoxy- polar 1 phenylamino]quinoxalin-2-yl} amide OH 0 H H 10 N N-S \N o N N 15 "A57" 4 -Dimethylaminomethyl-N-(3-(2-[2-(2-hydroxy- 1,76 / 598.68 ethoxy)ethoxy]-3,5-dimethoxyphenylamino)- polar I quinoxalin-2-yl)benzenesulfonamide 0 20 ) N / NH 0 _; H N NO O 0 NN HO ' 25 hydrochloride 'H NMR (500 MHz, DMSO-d 6 + TFA-d 1 ) 6 8ppm] 8.25 (d, J = 2.8, 1H), 8.20 (d, J = 8.3, 2 H), 8.02 - 7.97 (m, IH), 7.77 (d, J = 8.3, 2H), 7.69 - 7.64 (m, 1 H), 7.47 - 7.36 (m, 2H), 6.40 (d, J = 2.8, 1 H), 4.42 (s, 2H), 4.07 - 3.98 (m, 30 2H), 3.83 (s, 6H), 3.54 - 3.47 (m, 2H), 3.43 (t, J = 5.2, 2H), 3.37 (t, J = 5.2, 2H), 2.79 (s, 6H) 35 WO 2012/052102 PCT/EP2011/004746 -115 "Al 09" 3-Dimethylaminomethyl-N-{3-[2-(3-hydroxy- 1.79 / 568.7 propoxy)-3,5-dimethoxyphenylamino]quinoxalin-2- polar yl}benzenesulfonamide 5 / N H0 10 N OH "A110" 4-(3,3-Difluoroazetidin-1-yimethyl)-N-{3-[2-(3- 2.30 / 616.7 hydroxypropoxy)-3,5-dimethoxyphenylamino]- polar quinoxalin-2-yl}benzenesulfonamide 15 0 F N 0 Ft 0 NHH 0 '0 NHON 20 N OH "A 11" 4 -Azetidin-1-ylmethyl-N-{3-[2-(3-hydroxypropoxy)- 1.78 / 580.7 3,5-dimethoxyphenylaminoquinoxalin-2-yl}- polar benzenesulfonamide 25 I N N A O N N O \W-NH H 0 30 N OH 35 WO 2012/052102 PCT/EP2011/004746 -116 "Al 16" 3-Azetidin-l -ylmethyl-N-{3-[2-(3-hydroxypropoxy)-| 1.80 / 580.7 3,5-dimethoxyphenylamino]quinoxalin-2-yl}- polar benzenesulfonamide HO 5 Q N N O 0 0 -N N 10 0 "Al 29" 1-(2-Dimethylaminoethyl)-l H-pyrazole-3-sulfonic 1.77 / 586.7 acid {3-[2-(3-hydroxybutoxy)-3,5-dimethoxy- polar 15 phenylamino]quinoxalin-2-yl} amide NI 0n 0 \N NH H I N S 0 20 N \ NU OH "A130" 1-(2-Dimethylaminoethyl)-1 H-pyrazole-3-sulfonic 1.74 / 572.7 acid {3-12-(3-hydroxypropoxy)-3,5-dimethoxy- polar 25 phenylamino]quinoxalin-2-yl} amide O N J: 0 NH \\ NH H 0 30 N S N /N OH 35 WO 2012/052102 PCT/EP20111/004746 -117 Example 5 Preparation of 4-aminomethyl-N-{3-[2-(3-hydroxypropoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-yl}benzenesulfonamide ("A106") 5 0 0 N NI- N NH

H

2 , Raneyl Ni, THF N OH 10 N N NNH OH OK N o s=o 0s0o I N 15 N NH2 1.15 g of 4 -cyano-N-{3-[2-(3-hydroxypropoxy)-3,5-dimethoxyphenylamino] quinoxalin-2-yl}benzenesulfonamide in 5 ml of THF and 12 ml of methanolic 20 ammonia solution (10%) are hydrogenated in a suitable pressure apparatus in the presence of 1.00 g of sponge nickel catalyst (Johnson-Matthey) at 50*C and 5 bar for 17 hours. The catalyst is filtered off, rinsed with copious MeOH and THF, and the entire filtrate is evaporated, giving 819 mg of 4-aminomethyl-N-{3-[2-(3-hydroxypropoxy)-3,5-dimethoxyphenylamino] 25 quinoxalin-2-yl}benzenesulfonamide having a content of 82.4% (yield 59.4%); MS-FAB (M+H t ) = 540.2; Rf (polar method): 1.75 min. Example 6 30 Preparation of N-(4-{3-[2-(3-hydroxypropoxy)-3,5-dimethoxyphenylamino] quinoxalin-2-ylsulfamoyl}benzyl)acetamide ("A132") 35 WO 2012/052102 PCT/EP2011/004746 -118 O DAPECI, O 5 0 Rt, overnight OHXN ON OH O OH OOH 10 H2N HN -A-O 15 100 mg of 4 -aminomethyl-N-{3-[2-(3-hydroxypropoxy)-3,5-dimethoxyphenyl amino]quinoxalin-2-yl}benzenesulfonamide (content 82%), 37 mg of DAPECI and 8.7 jI of acetic acid in I ml of DMF are stirred at RT overnight in a screw cap vial. The reaction solution is poured into water, and the deposited precipitate is filtered off with suction. Purification by preparative HPLC on 20 silica gel RP18 (acetonitrile, water) gives a total of 39 mg of N-(4-{3-[2-(3 hydroxypropoxy)- 3 ,5-dimethoxyphenylamino]quinoxalin-2-ylsulfamoyl}benzyl) acetamide (yield 41%); MS-FAB (M+H 4 ) = 582.2; Rf (polar method): 2.19 min. 25 Pharmacological data P13 kinase inhibition 30 Compared with other quinoxaline derivatives disclosed in WO 2008/101979, the compounds according to the invention have improved inhibiting properties on P13 kinase. 35 WO 2012/052102 PCT/EP2011/004746 - 119 Table I Qompound No. IC50 Compounds from WO IC0 (cell) 2008/101979 (cell) I I 96 nM 370 nM 5 H N NH N HOH N NH aN NH N >JNH N N NH 10 0 N "A86" Example 28 4.6 nM 1100 nM 15 OH O OH N N NH N N NH 20 "A28" Example 47 S- 38 nM [ 4900 nM 0 N0 25 OH O o OS "A9 3" 30 Example 37 35 WO 2012/052102 PCT/EP2011/004746 - 120 53 nM 970 nM O O O'~H OOH 5 HH N NNH Ni: NH 5 N'NH N INH O O Example 63 10 "A35" 1 I 1.4 nM 290 nM OOH 0OH NOH 5 N NH NINH N yN 15 a NINH 0 01 F F "A53" Example 36 2 I86 nM 2600 nM 20 1 0 N Ni NNH N N~NH ccNH I N 1NH ::o:S 25 0 0 N "A55" Example 68 I | 96 nM | 985 nM 30 H O N NHcN N N NH N O Q 35 "A86" (comparative substance from WO 2007/023186) WO 2012/052102 PCTIEP2011/004746 - 121 P13 kinase inhibition Table 2 5 Compound IC5o 050 Compound IC50 IC50 No. (enzyme) (cell) No. (enzyme) (cell) "Al" B "A46" "A2" B "A47" A "A3" A "A48" A 10 "A4" B "A49" A "A5" B "A50" A "A6" A "A51" A "A7" B "A52" B 15 "A8" "A53" A "A9" B "A54" B "Al0" B "A55" A "Al1" B "A56" B 20 "A12" B "A57" B "A13" B "A58" A "A14" B "A59" A "A15" C "A60" A "A16" C "A61" B 25 "All" C "A62" B "A18" C "A63" B "A19" "A64" A "A20" "A65" B 30 "A21" C "A66" A "A22" A "A67" B "A23" B "A68" B "A69" B 35 "A25" B "A70" A "A26" B "A71"

A

WO 2012/052102 PCT/EP2011/004746 -122 "A27" B "A72" A "A28" A "A73" B "A29" A "A74" A 5 "A30" A "A75" B "A31" B "A76" A "A32" B "A77" B "A33" B "A78" A "A34" B "A79" B 10 "A35" A "A8" A "A36" A "A81" B "A82" A "A38" A "A86f A 15 "A39" A "A88" B "IA40" A "A89" A "A41" A "A90" B "A42" A "A91" A "A43" B "A92" B 20 "A447 A "A93" B "A45" A "A94" B "A95" B "Al 14" B 25 "A96" B "A115" A "A97" B "A116" A "A98" B "Al17" A "A99" A "Al18" B "A100" A "FA119"1 B 30 "AlOl" A "A120" A "A102" A "A121" A "A103" A "A122" A "A104" A "A123" B 35 "A05 1 B "A124" B "A106" A "A125"

A

WO 2012/052102 PCT/EP2011/004746 - 123 "A107" B "A126" B "A108" B "A127" B "A109" A "A128" B "Al 10" A "A129" A 5 "Al 11" B "A130" A "A112" B "A131" A "A113" B "A132" A 10 IC50: 1 nM - 0.1 M =A 0.1 pM - 10 paM = B > 10pM = C 15 20 25 30 35 WO 2012/052102 PCT/EP2011/004746 - 124 The following examples relate to medicaments: 5 Example A: Injection vials A solution of 100 g of an active compound of the formula I and 5 g of di sodium hydrogenphosphate in 3 I of bidistilled water is adjusted to pH 6.5 10 using 2 N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilised under sterile conditions and sealed under sterile conditions. Each injection vial contains 5 mg of active compound. 15 Example B: Suppositories A mixture of 20 g of an active compound of the formula I with 100 g of soya lecithin and 1400 g of cocoa butter is melted, poured into moulds and 20 allowed to cool. Each suppository contains 20 mg of active compound. Example C: Solution A solution is prepared from 1 g of an active compound of the formula 1, 25 9.38 g of NaH 2

PO

4 - 2 H 2 0, 28.48 g of Na 2

HPO

4 - 12 H 2 0 and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to 6.8, and the solution is made up to I I and sterilised by irradiation. This solution can be used in the form of eye drops. 30 Example D: Ointment 500 mg of an active compound of the formula I are mixed with 99.5 g of 35 Vaseline under aseptic conditions.

- 125 Example E: Tablets A mixture of 1 kg of active compound of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed in a conventional manner to give tablets in such a way that each tablet contains 10 mg of active compound. Example F: Dragees Tablets are pressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, traga canth and dye. Example G: Capsules 2 kg of active compound of the formula I are introduced into hard gelatine capsules in a conventional manner in such a way that each capsule con tains 20 mg of the active compound. Example H: Ampoules A solution of 1 kg of active compound of the formula I in 60 I of bidistilled water is sterile filtered, transferred into ampoules, lyophilised under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active compound. It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.

- 125a In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention. 10 15 20 25 30 35

Claims (5)

1. A compound selected from the group No. Name and/or structure "Al" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(6-methoxybenzo-1,3 dioxol-4-ylamino)quinoxalin-2-yl] amide -N N-^ N 0 0 "A2" 4-Cyano-N-{3-[2-(3-dimethylaminopropyl)-3,5-dimethoxy phenylamino]quinoxalin-2-yl}benzenesulfonamide 0 N NN "A3" 4-Cyano- N-(3-{2-[3-(1, 1-dioxo- 1-lam bda*6*-thiomorpholin-4-yl) propyl]-3,5-dimethoxyphenylaminolquinoxalin-2-yl) benzenesulfonamide N 0 N-E S-N N 0.~ H H SN 0 01, /- /N0 -5-H HN - 127 "A4" 1-Methyl-1 H-imidazole-4-sulfonic acid (3-{2-[3-(l 1 -dioxo-1 lambda*6*-thiomorpholin-4-yl) propyl]-3,5-dimethoxy phenylamino}quinoxalin-2-yl) amide o 0 N NH N H CN I 0~ 11 0 s ~N 0 0 /N "A5" 1-Methyl-1H-imidazole-4-sulfonic acid [3-(2-hydroxymethyl-5 methoxy-2,3-dihydrobenzofuran-7-ylamino)quinoxalin-2-yl] amide 0 N N N NH H0 -N O 00 -N N HO "A6" 4-Cyano-N-{3-[2-(4-hydroxybutyl)-3,5-dimethoxyphenylamino] quinoxalin-2-yl}benzenesulfonamide 0 N N N 0 I IOH - 128 "A7" 1-Methyl-1 H-imidazole-4-sulfonic acid {3-[2-(4-hydroxybutyl) 3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide 0 N N l-' 0 H _ NH /Z- I I -N 0 OH "A8" 4-[3-(7-Methoxy-2,3-dihydrobenzo-1,4-dioxin-5-ylamino) quinoxalin-2-ylsulfamoyl]-N, N-dimethylbenzamide I N NH o~q 0 N XH "A9" 5-Methoxy-7-[3-(1 -methyl-1 H-imidazole-4-sulfonylamino) quinoxalin-2-ylamino]benzofuran-2-carboxylic acid dimethyl amide 0 N N N O NH R AH H 0% -N 0 -- N \fN - 129 "Al 0" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(7-methoxy-2,3 dihydrobenzo-1,4-dioxin-5-ylamino)quinoxalin-2-yl] amide 0 0 0 NH NA N - N OO N 0 "Al 1" 1-Methyl-1H-imidazole-4-sulfonic acid [3-(2,5-dimethoxy-3 methylphenylamino)quinoxalin-2-yl] amide O N N H H N N-S O N N "Al 2" 4-[3-(2,5-Dimethoxy-3-methylphenylamino)quinoxalin-2 ylsulfamoyl]-N, N-dimethylbenzamide 0 NN /NH N H H -130 "A13" 4-[3-(2-Ethyl-3,5-dimethoxyphenylamino)quinoxalin-2 ylsulfamoyl]-N, N-dimethylbenzamide 0 H- H N -N N-SO N o N N "Al 4" 1-Methyl-1H-imidazole-4-sulfonic acid [3-(2-ethyl-3,5-dimethoxy phenylamino)quinoxalin-2-yl] amide 0 H 0 N N N-S o N N "Al 5" 4-[3-(5-Methoxybenzofuran-7-ylamino)quinoxalin-2-ylsulfamoyl] N, N-dimethylbenzamide 0 0\I 0 NH0 //H O N "Al 6" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(5-methoxybenzofuran

7-ylamino)quinoxalin-2-yl] amide -131 "Al7" 1-Methyl-1H-imidazole-4-sulfonic acid [3-(3-ethyl-2,5-dimethoxy phenylamino)quinoxalin-2-yl] amide 0 -N N-S "Al 8" 4-[3-(3-Ethyl-2,5-dimethoxyphenylamino)quinoxalin-2 ylsulfamoyl]-N, N-dimethylbenzamide 0 HiP- N N N-SON 0 0 O N N "Al 9" 1-Methyl-1H-imidazole-4-sulfonic acid [3-(2-bromo-3,5 dimethoxyphenylamino)quinoxalin-2-yl] amide 0 \ / Br NH N N- N &NH0 "A20" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(2-chloro-3,5 dimethoxyphenylamino)quinoxalin-2-yl] amide 0 O - -CI NH N- 0 N==\ S //N-S \N N 0 - 132 "A21" Pyridine-4-sulfonic acid {3-[2-(3-hydroxypropoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-yl} amide 0 0 NH N S -NO K-N "A22" Thiazole-5-sulfonic acid {3-[2-(3-hydroxypropoxy)-3,5 dimethoxyphenylamino]quinoxalin-2-yl} amide o N H N SS N 0 "A23" 1-(2-Dimethylaminoethyl)-1 H-pyrazole-4-sulfonic acid {3-[2-(3 hydroxypropoxy)-3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide OH -O 0 H H -0 N Y N-C N 0 N N -133 "A24" 1-Methyl-1 H-pyrazole-3-sulfonic acid {3-[2-(3-hydroxypropoxy) 3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide N N 0 N N 11IH H 0 0 HO "A25" N-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxyphenylamino] quinoxalin-2-yl}-methanesulfonamide o Os N NH N NH "A26" N-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxyphenylamino] quinoxalin-2-yl}-2-methoxybenzenesulfonamide I N 0 N 1,0kN O NH 0 OO I OH -134 "A27" 2-(4-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxyphenylamino] quinoxalin-2-ylsulfamoyl}pyrazol- 1 -yl)-N, N-dimethylacetamide O N N 0 - N, S- N N / N 1 H H ,F0 0 HO "A28" 2-Dimethylaminomethyl-1 -methyl-1 H-imidazole-4-sulfonic acid {3-[2-(3-hydroxybutoxy)-3,5-dimethoxyphenylamino]quinoxalin 2-yl} amide N N O 1N IH H N O 0 HO "A29" 1-Difluoromethyl-1H-pyrazole-4-sulfonic acid {3-[2-(3-hydroxy propoxy)-3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide F H N N O 0 1-F0 0 HO -135 "A30" N-{3-[2-(3- Hydroxypropoxy)-3,5-dimethoxyphenylam ino] quinoxalin-2-yl}benzenesulfonamide 0 N N H it NH OH "A31" 2-Dimethylaminomethyl-1 -methyl-1 H-imidazole-4-sulfonic acid [3-(2,3,5-trimethoxyphenylamino)quinoxalin-2-yl] amide O N N 0 ~N - N 1N IH H N O -O 0 7Ns "A32" 1-Methyl-1 H-imidazole-4-sulfonic acid {3-[2-(3-hydroxy-2 methylpropoxy)-3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide 0N N N 0 HO 0 0 -- OH - 136 "A33" 2-Dimethylaminomethyl-1 -methyl-1 H-imidazole-4-sulfonic acid {3-[2-(3-hydroxypropoxy)-3,5-dimethoxyphenylam ino]quinoxalin 2-yl} amide -N N- O N 0 0 0 N_ HO "A34" Ethyl (4-{3-[2-(3-hydroxypropoxy)-3,5-dimethoxyphenylamino] quinoxalin-2-ylsulfamoyl}phenyl)carbamate P/N N 0 H 11 S-H Ni0 0 0 0 HO "A35" 1, 1-Dioxotetrahydro-1-lambda*6*-thiophene-3-sulfonic acid {3 [2-(3-hydroxypropoxy)-3,5-dimethoxyphenylamino]quinoxalin-2 yl} amide 0 N N 0 0 H IINH 0 0O 0 OH -137 "A36" 3-Methanesulfonylpropan-1-sulfonic acid {3-[2-(3-hydroxy propoxy)-3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide 0 N0 N N H 0 OH "A38" 4-Dimethylaminomethyl-N-{3-[2-(3-hydroxypropoxy)-3,5 dimethoxyphenylamino]quinoxalin-2-yl} benzenesulfonamide "A39" C,C,C-Trifluoro-N-{3-[2-(3-hydroxypropoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-yl}methanesulfonamide 0~ N O N NJ 0 T H 0 F F>Kr F OH "A40" C,C,C-Trifluoro-N-[3-(2,3,5-trimethoxyphenylamino)quinoxalin-2 yl]methanesulfonamide N N 0 F 0 O 0 - 138 "A41" 5-Cyanothiophene-2-sulfonic acid {3-[2-(2-methanesulfonyl ethoxy)-3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide N O N 0 o H O\ NH O 00 "A42" 1-Methyl-1 H-imidazole-4-sulfonic acid {3-[2-(3-hydroxybutoxy) 3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide 0 N T NH O NOH HO "A4311 1 -Methyl-i1 H-pyrazole-4-sulfonic acid {3-[2-(3-hydroxybutoxy) 3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide 0 N . N'40 T H N OH -139 "A44" 1-Methyl-1 H-pyrazole-4-sulfonic acid {3-[2-(3-hydroxypropoxy) 3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide N N 0 N 1 N 0 O 0 HO "A45" 4-Cyano-N-{3-[2-(3-hydroxybutoxy)-3,5-dimethoxyphenylamino] quinoxalin-2-yl}benzenesulfonamide 0 N NH O N "A46" 2-Cyano-N-{3-[2-(3-hydroxypropoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-yl}benzenesulfonamide : 1 0 ?-I N N 0 HH O\\"'NH 0 N OH -140 "A47" 1-Methyl-1 H-imidazole-4-sulfonic acid (3-{3,5-dimethoxy-2-[2-(2 methoxyethoxy)ethoxy]phenylamino}quinoxalin-2-yl) amide 0 N O\, ',NH O0 N O0 N "A48" 4-Cyano-N-(3-{3,5-dimethoxy-2-[2-(2-methoxyethoxy)ethoxy] phenylamino}quinoxalin-2-yl)benzenesulfonamide 7 0 De N N "A49" C,C,C0-Trifluoro- N-(3-{2-[2-(2-hydroxyethoxy)ethoxy]-3, 5 dimethoxyphenylam ino}quinoxalin-2-yl) methanesulfonam ide 0 0 N NH N/ N F -141 "A50" N-(4-{3-[2-(3- Hydroxypropoxy)-3,5-dimethoxyphenylam ino] quinoxalin-2-ylsulfamoyl}phenyl)acetamide /N 0N N % -NH H O HN-O / 0 HO "A51" 5-Cyanothiophene-2-sulfonic acid {3-[2-(3-hydroxypropoxy)-3,5 dimethoxyphenylamino]quinoxalin-2-yl} amide 0 N NO N OHA O N H H 1 ~NN O N-S O N N0 O=S- -142 "A53"1 4- Fl uoro- N- (3-{2- [2- (2-hyd roxyethoxy) ethoxy]-3,5-d imethoxy phenylam inolq ui noxal in-2-yl) benzenesulfonam ide o__ of//OH NH N F "A54" 1-Methyl-1 H-imidazole-4-sulfonic acid {3-[3,5-dimethoxy-2-(2 morpholin-4-ylethoxy)phenylamino]quinoxalin-2-yl} amide O NH N o NN "A55" 1-Methyl-1 H-imidazole-4-sulfonic acid {3-[2-(2-methanesulfonyl ethoxy)-3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide 0 N OON N o 0 O 0 0N N N6 -143 "A57" 4- Dimethylam inomethyl-N-(3-{2-[2-(2-hydroxyethoxy)ethoxy] 3,5-dimethoxyphenylamino}quinoxalin-2-yl)benzenesulfonam ide 0 OO NH oH O- N 0"O HO "A58" N-(3-{2-[2-(2-Hydroxyethoxy)ethoxy]-3,5-dimethoxy phenylamino}quinoxalin-2-yl)benzenesulfonam ide NO N N ' o O\NH H 0 OH "A59" 5-Cyanothiophene-2-sulfonic acid (3-{2-[2-(2-hydroxyethoxy) ethoxy]-3,5-dimethoxyphenylamino}quinoxalin-2-yl) amide N 0 H N HO,,, - 0OO -144 "A60" Thiophene-2-sulfonic acid [3-(2-{2-[(2-hydroxyethyl) methyl amino]ethoxy}-3,5-dimethoxyphenylamino)quinoxalin-2-yl] amide N N 0 HO N ON 0 H 0 0 "A61" N-(3-{2-[2-(2-Hydroxyethoxy)ethoxy]-3,5-dimethoxy phenylamino}quinoxalin-2-yl)-4-methoxybenzenesulfonamide -O 0 O 0 N-S0 00 O O N N "A62" N-[4-(3-{2-[2-(2-Hydroxyethoxy)ethoxy]-3,5-dimethoxy phenylamino}quinoxalin-2-ylsulfamoyl)phenyl]acetamide \/(> OH NO 0 N N O O 0 0 "A63" 3-Cyano-N-(3-{2-[2-(2-hydroxyethoxy)ethoxy]-3,5-dimethoxy phenylamino}quinoxalin-2-yl)benzenesulfonamide / OH / N N zN 0 0 H H 0 0 N -145 "A64" Thiophene-2-sulfonic acid (3-{2-[2-(2-hydroxyethoxy)ethoxy] 3,5-dimethoxyphenylamino}quinoxalin-2-yl) amide N N O OH 00 0 "A65" Pyridine-3-sulfonic acid (3-{2-[2-(2-hydroxyethoxy)ethoxy]-3,5 dimethoxyphenylamino}quinoxalin-2-yl) amide OH N N O 0 O-O 0 0 "A66" Thiophene-2-sulfonic acid {3-[2-(2-hydroxyethoxy)-3,5 dimethoxyphenylamino]quinoxalin-2-yl} amide OH SO Nl N0 "A67" Pyridine-3-sulfonic acid (3-{2-[2-(2-hydroxyethanesulfonyl) ethoxy]-3,5-dimethoxyphenylamino}quinoxalin-2-yl) amide HO 0 N N N 0O SS-N N ii "H H 0 0

10- -146 "A68" Pyridine-3-sulfonic acid [3-(2-{2-[(2-hydroxyethyl)-methylamino] ethoxy}-3,5-dimethoxyphenylamino)quinoxalin-2-yl] amide PN 0 N\ SHO 0 0 "A69" 4-(3-{2-[2-(2-Hydroxyethoxy)ethoxy]-3,5-dimethoxy phenylamino}quinoxalin-2-ylsulfamoyl)-N, N-dimethylbenzamide () OH N xXN O O -NN N N 0 0 "A70" 4-Cyano- N-{3-[3,5-dimethoxy-2-(2-morpholin-4-ylethoxy) phenylamino]quinoxalin-2-yl}benzenesulfonamide NC0 / N~ ,N O0 O S-N N 00 00 "A71" 3,4- Difluoro- N-{3-[2-(3-hydroxypropoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-yl}benzenesulfonamide F S-N N0 F "H H O F HO,, A -147 "A72" 4-Cyano-N-(3-{2-[2-(2-hydroxyethanesulfinyl)ethoxy]-3,5 dimethoxyphenylamino}quinoxalin-2-yl)benzenesulfonam ide 0 O' NH "O H ON ;j ON S N O OH N "A73" 3,4-Difluoro-N-(3-{2-[2-(2-hydroxyethoxy)ethoxy]-3,5-dimethoxy phenylamino}quinoxalin-2-yl)benzenesulfonamide N -4N O F S-N N F H H F H0--7O/--" o 0 "A74" 4-Cyano-N-{3-[2-(2,3-dihydroxypropoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-yl}benzenesulfonamide HO HO N N O 0 N S-N N -a "H H 0 0- -148 "A75" 1-Methyl-1 H-imidazole-4-sulfonic acid {3-[2-(2,3-dihydroxy propoxy)-3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide HO OH _N N-O0 N H1 H 0 /0 "A76" 4-Cyano-N-(3-{2-[2-(2-hydroxyethanesulfonyl)ethoxy]-3,5 dimethoxyphenylamino}quinoxalin-2-yl)benzenesulfonamide HO 0N N O O N--I -N N 0 "A77"1 1-Methyl-1 H-imidazole-4-sulfonic acid (3-{2-[2-(2-hydroxy ethanesulfonyl)ethoxy]-3,5-dimethoxyphenylaminolquinoxalin-2 yl) amide HO 00 0N N O O N 0 -149 "A78" 4-Cyano-N-[3-(2-{2-[(2-hydroxyethyl) methylam ino]ethoxy}-3,5 dimethoxyphenylam ino)quinoxalin-2-yl]benzenesulfonam ide 0~~ N I N N H0 i 0 N NN OH "A79" Pyridine-3-sulfonic acid {3-[2-(3-hydroxypropoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-yl} amide N O N - N, 0 O H 0 N OH "A80" 4-Cyano-N-(3-{2-[2-(2-hydroxyethoxy)ethoxy]-3,5-dimethoxy phenylamino}quinoxalin-2-yl)benzenesulfonamide N \/N 0 N-- -N N 0 HO,0 0 -150 "A81" 1-Methyl-1 H-imidazole-4-sulfonic acid (3-{2-[2-(2-hydroxy ethoxy)ethoxy]-3,5-dimethoxyphenylamino}quinoxalin-2-yl) amide N N 0 L SN N0 N 0 O H 0 0 "A82" 4-Cyano-N-{3-[2-(3-hydroxypropoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-yl}benzenesulfonamide N N 0 -- S-N N 0 0 0 HO, - / "A83" 1-Methyl-1H-imidazole-4-sulfonic acid [3-(5-difluoromethoxy-2,3 dimethoxyphenylamino)quinoxalin-2-yl] amide 5?/ 0N N O O 011 IH H H 0 F F -151 "A84" 4-Cyano- N-[3-(5-difluoromethoxy-2,3-dimethoxyphenylam ino) quinoxalin-2-yl]benzenesulfonam ide N NO 0 N- - N 0 O F "A85" 4-[3-(5-Difluoromethoxy-2,3-dimethoxyphenylamino)quinoxalin 2-ylsulfamoyl]-N, N-dimethylbenzamide F H-, 0 F O O NH O0 N N "A86" 1-Methyl-1 H-imidazole-4-sulfonic acid {3-[2-(3-hydroxypropoxy) 3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide HO _N N-O0 11 N O 00 - 152 "A87" 4-{3-[2-(3- Hydroxypropoxy)-3,5-dimethoxyphenylam ino] quinoxalin-2-ylsulfamoyl}-N, N-dimethylbenzamide 0- OH O 0 NH N 0 O - ~ / // N o N "A88" 4-{3-[2-(2-Hydroxyethoxy)-3,5-dimethoxyphenylamino] quinoxalin-2-ylsulfamoyl}-N, N-dimethylbenzamide 0- OH O 0 NH N- O ~ O / N N 0-S 0 N O N "A89" 1-Methyl-1 H-imidazole-4-sulfonic acid {3-[2-(2-hydroxyethoxy) 3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide /N 0 O 0 N HO "A90" N,N-Dimethyl-4-[3-(2,3,5-trimethoxyphenylamino)quinoxalin-2 ylsulfamoyl]benzamide 0 H- H PN 00 ON0 -153 "A91" 4-Cyano-N-[3-(2,3,5-trimethoxyphenylamino)quinoxalin-2-yl] benzenesulfonamide -O -00 H Hi P N N-S N -O O N N I 0 "A92" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(2,3,5-trimethoxy phenylamino)quinoxalin-2-yl] amide -O NN-S\) O N -O O N N "A93" N-{3-[2-(3- Hydroxybutoxy)-3,5-dimethoxyphenylam no] quinoxalin-2-yI}-methanesulfonam ide 0 0 N N 0 ,/NH OH S=O "A94" 2-Dimethylaminomethyl-1 -methyl-1 H-imidazole-4-sulfonic acid {3-[2-(4-hydroxybutyl)-3,5-dimethoxyphenylamino]quinoxalin-2 yl} amide OH 0N -O i N-S \N O \ N 0 N N -154 "A95" 4-{3-[2-(3- Hydroxypropoxy)-3,5-dimethoxyphenylam ino] quinoxalin-2-ylsulfamoyl}-N-(2,2,2-trifluoroethyl)benzamide 0~ N O F F N 0 NIIH H O HN O O OH "A96" 2-Cyanoethanesulfonic acid {3-[2-(3-hydroxypropoxy)-3,5 dimethoxyphenylamino]quinoxalin-2-yl} amide ON 0 0 HI NH 0 N 0 OH "A97" 3-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxyphenylamino] quinoxalin-2-ylsulfamoyl}-N, N-dimethylbenzamide N N O 0 IH H 0 = 0 0 N HO -155 "A98" 4-(3,3- Difluoroazetidine- 1 -carbonyl)- N-{3-[2-(3-hydroxypropoxy) 3,5-dimethoxyphenylamino]quinoxalin-2-yl}benzenesulfonamide F N 0 F

11-NH H N O O OH "A99" N-{3-[2-(3- Hydroxybutoxy)-3,5-dimethoxyphenylam ino] quinoxalin-2-yl}methanesulfonamide 0 -N N0 N H 0 NH OH S=O "A100" 1-Methyl-1 H-pyrazole-3-sulfonic acid {3-[2-(3-hydroxybutoxy) 3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide '~0 N N N 0 0 NH 00 -N' 0 OH - 156 "A101" Thiazole-5-sulfonic acid {3-[2-(3-hydroxybutoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-yl} amide 0~ N N l NH 0 o TOH O NH O s N O OH "Al102"1 4-(Azetidine-l1-carbonyl)- N-{3-[2-(3-hydroxypropoxy)-3, 5 dimethoxyphenylam ino]quinoxalin-2-yIlbenzenesulfonam ide 0~ N0 0 H4 00 OH 0 "Al103"1 1- Difluoromethyl-l1H-pyrazole-4-sulfonic acid {3-[2-(3-hydroxy butoxy)-3,5-dimethoxyphenylamino]quinoxalin-2-yI amide 0 N N jN 0 0 TH4 I \\NH 0 F S\ N 0 F N O H -157 "A104" OO 0 N NH N NH OH O=6=0 "A105" 3-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxyphenylamino] quinoxalin-2-ylsulfamoyl}-N-(2,2,2-trifluoroethyl)benzamide o' O~aIN // N NH O H HN 0 F F F HO O "Al 06" 4-Am inomethyl-N-{3-[2-(3-hydroxypropoxy)-3,5 dimethoxyphenylam ino]quinoxalin-2-yl} benzenesulfonamide "A107" 3-(3,3-Difluoroazetidine-1-carbonyl)-N-{3-[2-(3-hydroxypropoxy) 3,5-dimethoxyphenylamino]quinoxalin-2-yl}benzenesulfonamide N O N0 N/ H N F O Os HO F - 158 "A108" 3-(Azetidine- 1 -carbonyl)- N-{3-[2-(3-hydroxypropoxy)-3,5 dimethoxyphenylam ino]quinoxalin-2-yl}benzenesulfonam ide N N 0 11I H H\/ 0 OP 0 0 W HO "A109" 3- Dimethylam inomethyl-N-{3-[2-(3-hydroxypropoxy)-3,5 dimethoxyphenylam ino]quinoxalin-2-yl}benzenesulfonam ide H -- N N ~~~0 0 N H o N s N OH "A 110" 4-(3,3-Difluoroazetidin- 1 -ylmethyl)-N-{3-[2-(3-hydroxypropoxy) 3,5-dimethoxyphenylamino]quinoxalin-2-yl}benzenesulfonamide F N O F N H o NN N O F NOH -159 "Al 11" 4-Azetidin- 1 -ylmethyl- N-{3-[2-(3-hydroxypropoxy)-3,5 dimethoxyphenylam ino]quinoxalin-2-yl}benzenesulfonam ide 0 N N O O \ NH H N'O OH "Al 12" 1-Methyl-1 H-pyrazole-3-sulfonic acid (3-{2-[2-(2-hydroxyethoxy) ethoxy]-3,5-dimethoxyphenylamino}quinoxalin-2-yl) amide NN+N S-N N L\-I IH H 0 -0 0 0- HO "Al 13" 2-Dimethylaminomethyl-1 -methyl-1 H-imidazole-4-sulfonic acid {3-[2-(4-hydroxybutoxy)-3, 5-dimethoxyphenylam ino]quinoxalin 2-yl} amide N N N \NH H O N 0 N N OH -160 "Al 14" C,C-Difluoro-N-{3-[2-(3-hydroxypropoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-yl}methanesulfonamide 0 N O H 0 \NH 0 F F OH "Al 15" C,C-Difluoro-N-{3-[2-(3-hydroxybutoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-yl}-methanesulfonamide N N 0 H O F S-N N IIH H F O O 0 HO "Al 16" 3-Azetidin- 1 -ylmethyl- N-{3-[2-(3-hydroxypropoxy)-3,5 dimethoxyphenylamino]quinoxalin-2-yl}benzenesulfonamide HO O N /IN 0 0 SS-N N - 0 0- -161 "Al 17" 1-Methyl-1 H-pyrazole-3-sulfonic acid {3-[2-(4-hydroxybutyl)-3,5 dimethoxyphenylamino]quinoxalin-2-yl} amide N N 0 ~N N - SN N 11IH H 0 0 HO "Al 18" 2,2-Difluoro-2-(3-{3-[2-(3-hydroxybutoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-ylsulfamoyl}pyrazol-1-yl)-N, N dimethylacetamide "Al 19" 2,2-Difluoro-2-(3-{3-[2-(3-hydroxypropoxy)-3,5-dimethoxy phenylamino]quinoxalin-2-ylsulfamoyl}pyrazol-1-yl)-N,N dimethylacetamide 0 N F O N rN O_ 'N I'NH H O /NN F 0 - 0 HO "A120" 2-(3-{3-[2-(3-Hydroxybutoxy)-3,5-dimethoxyphenylamino] quinoxalin-2-ylsulfamoyl}pyrazol-1-yl)-N,N-dimethylacetamide O'' N ON N 0 N )-k N \ -NH H 0 O NN O0 / - 0 HO -162 "A121" 1-Methyl-1 H-pyrazole-3-sulfonic acid [3-(2,3,5-trimethoxy phenylamino)quinoxalin-2-yl] amide N N 0 N' S-N N 11 H H 0 -o 0 "A122" 2-(3-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxyphenylamino] quinoxalin-2-ylsulfamoyl}pyrazol-1-yl)-N,N-dimethylacetamide 0~~ N 0 H N S - -NO O= N 0 N- OH "A123" 2-Diethylaminomethyl-1 -methyl-1 H-imidazole-4-sulfonic acid {3 [2-(3-hydroxybutoxy)-3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide 0 N 0 N N '-NH H 00 \ N O HO -163 "A124" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(2-hydroxymethyl-7 methoxy-2,3-dihydrobenzo- 1,4-dioxin-5-ylam ino)quinoxalin-2-yl] amide 0~~ N I LO rj N 0 0 H NH 0 -N 0 OH WN "A125" 1-Methyl-1 H-pyrazole-3-sulfonic acid {3-[2-(3-hydroxy-3-methyl butoxy)-3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide N 0NN X / N O I\ S-N N0 0 HO-- O 0 "A126" 2-Diethylaminomethyl-1 -methyl-1 H-imidazole-4-sulfonic acid {3 [2-(3-hydroxypropoxy)-3,5-dimethoxyphenylamino]quinoxalin-2 yl} amide N N 0 N I H H HO - 164 "A127" 1-Methyl-1 H-imidazole-4-sulfonic acid [3-(3-hydroxymethyl-7 methoxy-2,3-dihydrobenzo- 1,4-dioxin-5-ylam ino)quinoxalin-2-yl] amide I0"1 N ON N" \\-NH H 0 S 0 0 N HO "A128" 2-Dimethylaminomethyl-1 -methyl-1 H-imidazole-4-sulfonic acid {3-[2-(3-hydroxy-3-methylbutoxy)-3,5-dimethoxyphenylamino] quinoxalin-2-yl} amide -N N IN IIH H 0O N-- Hoi j-0 0 HO "A129" 1-(2-Dimethylaminoethyl)-1 H-pyrazole-3-sulfonic acid {3-[2-(3 hydroxybutoxy)-3,5-dimethoxyphenylamino]quinoxalin-2-yl} amide O O~ 01 N NN OH -165 "A130" 1-(2-Dimethylaminoethyl)-1 H-pyrazole-3-sulfonic acid {3-[2-(3 hydroxypropoxy)-3,5-dimethoxyphenylam ino]quinoxalin-2-yl} amide N o 0 H NHo | N S N\ 0\ N- OH "A131" N, N-Dimethyl-2-{3-[3-(2,3,5-trimethoxyphenylamino)quinoxalin 2-ylsulfamoyl]pyrazol-1 -yl}acetamide Q N N 0 N 0H I-. IH H 0 0 0 "Al 32" N-(4-{3-[2-(3-Hydroxypropoxy)-3,5-dimethoxy phenylam ino]quinoxalin-2-ylsulfamoyl}benzyl)acetam ide or a pharmaceutically usable salt, tautomer and/or stereoisomer thereof, or a mixture thereof in any ratio. 2. A medicament comprising at least one compound of Claim 1 and/or a pharmaceutically usable salt, tautomer and/or stereoisomer thereof, or a mixture thereof in any ratio, and optionally an excipient and/or adjuvant. 3. Set (kit) consisting of separate packs of (a) an effective amount of a compound of Claim 1, and/or a pharmaceutically usable salt, tautomer and/or stereoisomer thereof, or a mixture thereof in any ratio, and - 166 (b) an effective amount of a further medicament active compound. 4. A pharmaceutical formulation comprising at least one compound of Claim 1 and/or a pharmaceutically usable salt, tautomer and/or stereoisomer thereof, or a mixture thereof in any ratio and an excipient and/or an adjuvant. 5. A pharmaceutical formulation comprising at least one compound of Claim 1 and/or a pharmaceutically usable salt, tautomer and/or stereoisomer thereof, or a mixture thereof in any ratio and an effective amount of a further active compound. 6. Use of a compound of Claim 1 or a pharmaceutically usable salt, tautomer and/or stereoisomer thereof, or a mixture thereof in any ratio; the medicament of Claim 2; or the pharmaceutical formulation of Claim 4 or 5, in the treatment of a disease or condition selected from one or more of the group consisting of an autoimmune disease, an inflammatory disease, a cardiovascular disease, a neurodegen erative disease, an allergy, asthma, pancreatitis, multiorgan failure, a kidney disease, blood platelet aggregation, a cancer, sperm motility, transplant rejection, graft rejection and a lung injury. 7. Use of a compound of Claim 1 or a pharmaceutically usable salt, tautomer and/or stereoisomer thereof, or a mixture thereof in any ratio, for the preparation of a medicament for the treatment or prevention of a disease or condition selected from one or more of the group consisting of an autoimmune disease, an inflammatory disease, a cardiovascular disease, a neurodegenerative disease, an allergy, asthma, pancreatitis, multiorgan failure, a kidney disease, blood platelet aggregation, a cancer, sperm motility, transplant rejection, graft rejection and a lung injury. -167 8. A method for the treatment of a disease or condition selected from one or more of the group consisting of an autoimmune disease, an inflammatory disease, a cardiovascular disease, a neurodegenerative disease, an allergy, asthma, pancreatitis, multiorgan failure, a kidney disease, blood platelet aggregation, a cancer, sperm motility, transplant rejection, graft rejection and a lung injury, comprising administering an effective amount of a compound of Claim 1 or a pharmaceutically usable salt, tautomer and/or stereoisomer thereof, or a mixture thereof in any ratio; the medicament of Claim 2; or the pharmaceutical composition of Claim 4 or 5, to a subject in need thereof. 9. A phosphoinositide 3-kinase inhibitor comprising a compound of Claim 1 or a pharmaceutically usable salt, tautomer and/or stereoisomer thereof, or a mixture thereof in any ratio. 10. A compound of Claim 1 or a pharmaceutically acceptable salt, tautomer and/or stereoisomer thereof, or a mixture thereof in any ratio, substantially as herein described with reference to the Examples. 11. The medicament of Claim 2, the set (kit) of Claim 3, the pharmaceutical formulation of Claim 4 or 5, the use of Claim 6 or 7, the method of Claim 8, or the phosphoinositide 3-kinese inhibitor of Claim 9, substantially as herein described with reference to the Examples.

12. A process for the preparation of a compound of Claim 1 and/or a pharmaceutically usable salt, tautomer and/or stereoisomer thereof, or a mixture thereof in any ratio; substantially as herein described with reference to the Examples.